Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-36792

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		98-0373793
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

305 College Road East
Princeton, New Jersey		08540
(Address of principal executive offices)		(Zip Code)

(732) 329-8885

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	CTSO	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☑	Smaller reporting company	☑
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes þ No

As of August 12, 2024, there were 54,429,617 shares of the issuer’s common stock, $0.001 par value per share (the “Common Stock”), outstanding.

Table of Contents

CytoSorbents Corporation

FORM 10-Q

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION

Item 1. Financial Statements		3

Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023		3
Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)		4
Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)		5
Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (unaudited)		6

Notes to Consolidated Financial Statements (unaudited)		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		28

Item 3. Quantitative and Qualitative Disclosures About Market Risk		38

Item 4. Controls and Procedures		39

PART II. OTHER INFORMATION

Item 1. Legal Proceedings		40

Item 1A. Risk Factors		40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		40

Item 3. Defaults Upon Senior Securities		40

Item 4. Mine Safety Disclosures		40

Item 5. Other Information		40

Item 6. Exhibits		41

Signatures		42

This Quarterly Report on Form 10-Q includes our trademarks and trade names, such as “CytoSorb,” “CytoSorb XL,” “ECOS-300CY,” “BetaSorb,” “ContrastSorb,” “DrugSorb,” “HemoDefend-RBC,” “HemoDefend-BGA,” “K⁺ontrol” and “VetResQ,” which are protected under applicable intellectual property laws and are the property of CytoSorbents Corporation and our subsidiaries. This Quarterly Report on Form 10-Q also contains the trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the ™, ®, or ^SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

CYTOSORBENTS CORPORATION

CONSOLIDATED BALANCE SHEETS


	June 30,
	2024		December 31,
	(Unaudited)		2023

ASSETS
Current Assets:
Cash and cash equivalents	$	8,458,708	$	14,131,137
Grants and accounts receivable, net of allowance of $88,017 as of June 30, 2024 and $49,663 at December 31, 2023		7,822,823		6,057,072
Inventories		4,316,752		3,680,129
Prepaid expenses and other current assets		1,357,017		1,834,485
Total current assets		21,955,300		25,702,823

Property and equipment, net		9,423,649		10,056,354
Restricted cash		6,483,958		1,483,958
Right-of-use assets		11,789,539		12,058,896
Other assets		3,774,345		3,958,603
Total Assets	$	53,426,791	$	53,260,634

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	3,047,038	$	3,802,170
Current maturities of long-term debt		—		2,500,000
Lease liability – current portion		412,067		373,636
Accrued expenses and other current liabilities		6,877,163		7,870,149
Total current liabilities		10,336,268		14,545,955
Lease liability, net of current portion		12,680,725		12,896,659
Long-term debt		13,673,195		2,542,857
Total Liabilities		36,690,188		29,985,471

Commitments and Contingencies (Note 6)
Stockholders’ Equity:
Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023		—		—
Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,306,415 and 54,240,265 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		54,306		54,240
Additional paid-in capital		307,514,758		305,196,874
Accumulated other comprehensive income		2,173,818		529,321
Accumulated deficit		(293,006,279)		(282,505,272)
Total Stockholders’ Equity		16,736,603		23,275,163
Total Liabilities and Stockholders’ Equity	$	53,426,791	$	53,260,634

See accompanying notes to consolidated financial statements.

Table of Contents

CYTOSORBENTS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS


	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024		2023
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
Revenue:
CytoSorb sales	$	8,830,391	$	8,065,829	$	17,795,181	$	15,972,098
Other product sales		11,398		6,583		36,128		10,353
Total product sales		8,841,789		8,072,412		17,831,309		15,982,451
Grant income		1,052,847		1,348,409		1,849,619		2,887,866
Total revenue		9,894,636		9,420,821		19,680,928		18,870,317
Cost of revenue		3,391,907		3,402,271		6,607,621		7,396,440
Gross profit		6,502,729		6,018,550		13,073,307		11,473,877

Other expenses:
Research and development		1,519,618		3,668,804		3,767,811		7,883,219
Legal, financial and other consulting		820,732		1,185,031		1,501,437		1,854,264
Selling, general and administrative		7,581,201		7,723,952		16,148,400		16,187,226
Total expenses		9,921,551		12,577,787		21,417,648		25,924,709
Loss from operations		(3,418,822)		(6,559,237)		(8,344,341)		(14,450,832)

Other income (expense):
Interest income (expense), net		(180,098)		(8,821)		(186,750)		(71,992)
Gain (loss) on foreign currency transactions		(544,226)		414,974		(1,969,916)		1,075,656
Miscellaneous income (expense)		—		—		—		(31,799)
Total other income (expense), net		(724,324)		406,153		(2,156,666)		971,865

Loss before benefit from income taxes		(4,143,146)		(6,153,084)		(10,501,007)		(13,478,967)

Benefit from income taxes		—		—		—		—

Net loss attributable to common stockholders	$	(4,143,146)	$	(6,153,084)	$	(10,501,007)	$	(13,478,967)

Basic and diluted net loss per common share	$	(0.08)	$	(0.14)	$	(0.19)	$	(0.31)

Weighted average number of shares of common stock outstanding		54,306,041		44,015,380		54,284,416		43,758,888

Net loss	$	(4,143,146)	$	(6,153,084)	$	(10,501,007)	$	(13,478,967)
Other comprehensive income (loss):
Foreign currency translation adjustment		421,322		(392,674)		1,644,497		(1,000,882)
Comprehensive loss	$	(3,721,824)	$	(6,545,758)	$	(8,856,510)	$	(14,479,849)

See accompanying notes to consolidated financial statements.

Table of Contents

CYTOSORBENTS CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

For the three and six months ended June 30, 2024 and 2023 (Unaudited)


						Accumulated
				Additional		Other
	Common Stock			Paid-In		Comprehensive		Accumulated		Stockholders’
	Shares	Par value		Capital		Income (Loss)		Deficit		Equity
Balance at March 31, 2024	54,293,555	$	54,294	$	305,984,268	$	1,752,496	$	(288,863,133)	$	18,927,925
Stock-based compensation - employees, consultants and directors	—		—		828,580		—		—		828,580
Warrants issued in connection with long-term debt	—		—		690,709		—		—		690,709
Other comprehensive loss: foreign translation adjustment	—		—		—		421,322		—		421,322
Issuance of restricted stock units	12,860		12		11,201		—		—		11,213
Net loss	—		—		—		—		(4,143,146)		(4,143,146)
Balance at June 30, 2024	54,306,415	$	54,306	$	307,514,758	$	2,173,818	$	(293,006,279)	$	16,736,603

Balance at December 31, 2023	54,240,265	$	54,240	$	305,196,874	$	529,321	$	(282,505,272)	$	23,275,163
Stock-based compensation - employees, consultants and directors	—		—		1,562,788		—		—		1,562,788
Warrants issued in connection with long-term debt	—		—		690,709		—		—		690,709
Other comprehensive income: foreign translation adjustment	—		—		—		1,644,497		—		1,644,497
Issuance of common stock offerings, net of fees	53,290		54		53,186		—		—		53,240
Issuance of restricted stock units	12,860		12		11,201		—		—		11,213
Net loss	—		—		—		—		(10,501,007)		(10,501,007)
Balance at June 30, 2024	54,306,415	$	54,306	$	307,514,758	$	2,173,818	$	(293,006,279)	$	16,736,603


						Accumulated
				Additional		Other
	Common Stock			Paid-In		Comprehensive		Accumulated		Stockholders’
	Shares	Par value		Capital		Income (Loss)		Deficit		Equity
Balance at March 31, 2023	43,851,380	$	43,851	$	288,514,368	$	1,720,987	$	(261,323,761)	$	28,955,445
Stock-based compensation - employees, consultants and directors	—		—		570,235		—		—		570,235
Other comprehensive loss: foreign translation adjustment	—		—		—		(392,674)		—		(392,674)
Issuance of common stock offerings, net of fees	230,605		231		776,060		—		—		776,291
Proceeds from exercise of stock options for cash	56,393		56		154,772		—		—		154,828
Issuance of restricted stock units	55,318		55		183,600		—		—		183,655
Net loss	—		—		—		—		(6,153,084)		(6,153,084)
Balance at June 30, 2023	44,193,696	$	44,193	$	290,199,035	$	1,328,313	$	(267,476,845)	$	24,094,696

Balance at December 31, 2022	43,635,715	$	43,635	$	287,000,021	$	2,329,195	$	(253,997,878)	$	35,374,973
Stock-based compensation - employees, consultants and directors	—		—		1,400,516		—		—		1,400,516
Other comprehensive income: foreign translation adjustment	—		—		—		(1,000,882)		—		(1,000,882)
Issuance of common stock offerings, net of fees	428,270		428		1,474,296		—		—		1,474,724
Proceeds from exercise of stock options for cash	74,393		75		197,304		—		—		197,379
Issuance of restricted stock units	55,318		55		183,600		—		—		183,655
Legal/audit fees related to ATM offering	—		—		(56,702)		—		—		(56,702)
Net loss	—		—		—		—		(13,478,967)		(13,478,967)
Balance at June 30, 2023	44,193,696	$	44,193	$	290,199,035	$	1,328,313	$	(267,476,845)	$	24,094,696

See accompanying notes to consolidated financial statements.

Table of Contents

CYTOSORBENTS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS


	Six months		Six months
	ended		ended
	June 30,		June 30,
	2024		2023
	(Unaudited)		(Unaudited)
Cash flows from operating activities:
Net loss	$	(10,501,007)	$	(13,478,967)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued final fee		111,422		21,429
Non-cash compensation		199,096		(105,488)
Depreciation and amortization		797,873		660,589
Amortization of right-of-use asset		91,854		110,881
Write off of patent cost		249,642		292,806
Bad debt expense (recovery)		29,120		13,384
Stock-based compensation		1,562,792		1,400,516
Foreign currency translation (gain) loss		1,969,916		(1,075,656)
Changes in operating assets and liabilities:
Grants and accounts receivable		(1,952,413)		(1,271,716)
Inventories		(725,998)		1,449,881
Prepaid expenses and other current assets		574,181		1,649,776
Other assets		1,124		—
Accounts payable and accrued expenses		(2,032,014)		291,068
Net cash used in operating activities		(9,624,412)		(10,041,497)

Cash flows from investing activities:
Purchases of property and equipment		(63,421)		(300,221)
Payments for patent costs		(183,462)		(242,378)
Net cash used in investing activities		(246,883)		(542,599)
Cash flows from financing activities:
Proceeds from long-term debt		15,000,000		—
Repayment of long-term debt		(5,000,000)		—
Payment of final fee		(150,000)		—
Payment of loan costs		(640,375)		—
Equity contributions - net of fees incurred		53,250		1,418,022
Proceeds from exercise of stock options		—		197,379
Net cash provided by (used in) financing activities		9,262,875		1,615,401
Effect of exchange rates on cash		(64,009)		(24,348)
Net change in cash, cash equivalents and restricted cash		(672,429)		(8,993,043)

Cash, cash equivalents and restricted cash - beginning of period		15,615,095		23,832,026
Cash, cash equivalents and restricted cash - end of period	$	14,942,666	$	14,838,983

Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$	537,672	$	173,334

Supplemental disclosure of non-cash financing activities:
Warrants issued in connection with long-term debt	$	690,709	$	—
Issuance of restricted stock units	$	11,213	$	183,655

See accompanying notes to consolidated financial statements.

Table of Contents

CytoSorbents Corporation

Notes to Consolidated Financial Statements

(UNAUDITED)

June 30, 2024

1. BASIS OF PRESENTATION

The interim consolidated financial statements of CytoSorbents Corporation (the “Company”) have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair presentation of the Company’s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2024. The results for the three and six months ended June 30, 2024 and 2023, are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.

As of June 30, 2024, the Company’s cash, cash equivalents and restricted cash balances were approximately $14.9 million, including approximately $8.4 million in cash and cash equivalents and approximately $6.5 million in restricted cash, the unrestricted portion of which is not expected to fund the Company’s operations beyond the next twelve months from the issuance of these consolidated financial statements. This matter raises substantial doubt about the Company’s ability to continue as a going concern. As a result, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company continues to pursue additional milestones related to its recently announced Avenue debt facility that would increase its unrestricted cash position by up to $10 million. If these milestones are not achieved, we will need to raise additional capital to support our ongoing operations in the future. Meanwhile the Company continues to evaluate other traditional and alternative sources of capital, including additional less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors.

2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly-owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. In March 2016, the Company formed CytoSorbents Switzerland GmbH, a wholly-owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the second quarter of 2016, provides marketing and direct sales services in Switzerland. In November 2018, the Company formed CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the first quarter of 2019, provides marketing and direct sales services in Poland. In the third quarter of 2019, the Company formed CytoSorbents UK Limited, a wholly-owned subsidiary of CytoSorbents Medical, Inc., which is responsible for the management of the Company’s clinical trial activities in the United Kingdom. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing and direct sales services in the United Kingdom and the Republic of Ireland, a wholly-owned subsidiary of CytoSorbents Europe, GmbH. In October 2022, the Company formed CytoSorbents France SAS, a wholly-owned subsidiary of CytoSorbents Europe, GmbH, to provide marketing and direct sales services in France. In May 2023, the Company formed CytoSorbents India Private Limited to provide marketing and direct sales services in India. CytoSorb, the Company’s flagship product, was approved in the European Union (“EU”) in March 2011 and is currently being marketed and distributed in more than 75 countries around the world, as an effective extracorporeal cytokine absorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in critical illnesses that may result in massive inflammation, organ failure, and patient death. In May 2018, the Company received a label extension for CytoSorb covering use of the device for the removal of bilirubin and myoglobin which allows for the use of the device in the treatment of liver failure and trauma, respectively. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. In January 2020, CytoSorb

Table of Contents

received EU CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received EU CE Mark label expansion to include rivaroxaban removal for the same indication.

In April 2020, CytoSorb received United States Food and Drug Administration (“FDA”) Emergency Use Authorization (“EUA”) of CytoSorb for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.

In April 2020, the Company also announced that the FDA had granted Breakthrough Designation for its DrugSorb-ATR Antithrombotic Removal System for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of CytoSorbents’ technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), de novo 510(k) or premarket approval) consistent with the FDA’s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigative Device Exemption (“IDE”) to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) double-blind randomized control trial (“RCT”) for up to 120 patients in the United States to support FDA marketing approval. In July 2023, the Company announced that enrollment in the STAR-T trial has completed, and in August 2023, the Company announced completion of the STAR-T trial, following the last scheduled patient follow-up. In December 2023, the Company announced that the independent Data Safety Monitoring Board (the “DSMB”) performed a final review of the full unblinded data on all 140 patients in the STAR-T trial and concluded there were no issues with device safety, meeting the primary safety endpoint of the study. The Company has also performed the initial data analysis on the primary effectiveness endpoint of STAR-T trial. Based on this analysis, the study did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries. However, the study did demonstrate evidence of reduced bleeding complications, including serious bleeding events, in patients in the pre-specified isolated coronary artery bypass graft (“CABG”) surgery population, representing more than 90% of the overall study population. The topline results of 140-patient, double-blinded, multicenter, pivotal STAR-T randomized, controlled trial were featured as a late breaking presentation at the 104^th Annual Meeting of the American Association for Thoracic Surgery (AATS) held in Toronto, Canada on April 28, 2024. The Company believes the safety and effectiveness data from STAR-T will support the parallel regulatory submission of DrugSorb-ATR to the FDA and Health Canada in the third quarter of 2024.

In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, “Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D),” in the United States to support FDA marketing approval. The study has been postponed while the Company concentrates its clinical focus on STAR-T.

If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device will be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.

In May 2022, the Company announced that the Company entered into a three-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximately 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery and is well-known for their seminal publications on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.

In June 2024, the Company announced the launch and immediate availability of its PuriFi™ hemoperfusion machine in the EU, following approval and certification under the EU Medical Device Regulation (MDR). Prior to this, beginning in June 2022 the company had a non-exclusive agreement with Nikkiso Europe GmbH (“Nikkiso”) to distribute Nikkiso’s PureADJUST stand-alone

Table of Contents

hemoperfusion pump and accessories in a total of 14 countries. In September 2023, the distribution agreement with Nikkiso expired, and the Company indicated that it would not seek renewal of the agreement.

In August 2022, the Company entered into a Marketing Agreement (the “Marketing Agreement”) with Fresenius Medical Care Deutschland GmbH (“Fresenius”), which expands the Company’s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius’ critical care products by Fresenius’ marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the “Term”). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius’ current critical care platforms. The launch of this program is expected to occur in 2024.

The technology is based upon biocompatible, highly porous polymer sorbent beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology which, as of June 30, 2024, is protected by 22 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally. These patents and patent applications are directed to various compositions and methods of use related to the Company’s blood purification technologies and are expected to expire between 2024 and 2038, absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on the Company’s ongoing business.

Stock Market Listing

On December 17, 2014, the Company’s common stock, par value $0.001 per share, was approved for listing on the Nasdaq Capital Market (“Nasdaq”), and it began trading on Nasdaq on December 23, 2014 under the symbol “CTSO.” Previously, the Company’s common stock traded in the over-the-counter-market on the OTC Bulletin Board.

Basis of Consolidation and Foreign Currency Translation

The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly-owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited and CytoSorbents France SAS, wholly-owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited and CytoSorbents India Private Limited, wholly-owned subsidiaries of CytoSorbents Medical, Inc. All significant intercompany transactions and balances have been eliminated in consolidation.

Translation gains and losses resulting from the process of remeasuring into the United States of America dollar, the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. The Euro is the functional currency of the European Subsidiary. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(544,000) and $415,000 for the three months ended June 30, 2024 and 2023, respectively. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(1,970,000) and $1,076,000 for the six months ended June 30, 2024 and 2023, respectively. The Company translates assets and liabilities of all of its foreign subsidiaries at the exchange rate in effect at the consolidated balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders’ equity.

Table of Contents

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:


	June 30, 2024		December 31, 2023
Cash and cash equivalents	$	8,458,708	$	14,131,137
Restricted cash		6,483,958		1,483,958
Total cash, cash equivalents and restricted cash	$	14,942,666	$	15,615,095

Restricted Cash

The Company’s total restricted cash in the amount of $6,483,958 consists of cash of $5,000,000 which is restricted in accordance with the terms of the debt agreement with Avenue Capital Group (see Note 5), cash of $1,467,458 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $16,500 that the Company is obligated to maintain as collateral for the credit limit on the Company’s credit card accounts.

Grants and Accounts Receivable

Trade accounts receivable consist of amounts due from direct customers, distributors and agencies of the U.S. government and are presented at net realizable value. At each balance sheet date, the Company estimates an expected allowance for credit losses inherent in the Company’s accounts receivable portfolio based on historical experience, specific allowances for known troubled accounts, and other available evidence. In addition, also at each reporting date, this estimate is updated to reflect any changes in credit risk since the receivable was initially recorded. This estimate is calculated on a pooled basis where similar risk characteristics exist. The Company has identified the following portfolio segments: direct customers, distributors/strategic partners and the U.S. government.

A fixed reserve percentage for each pool is derived from a review of the Company’s historical losses in relation to the total pool. This estimate is adjusted quarterly for management’s assessment of current conditions, reasonable and supportable forecasts regarding future events, and any other factors deemed relevant by the Company. The Company believes historical loss information is a reasonable starting point in which to calculate the expected allowance for credit losses as the Company’s portfolio segments have remained constant over the Company’s historical evaluation period.

The Company writes off receivables when there is information that indicates the debtor is facing significant financial difficulty and there is no possibility of recovery. If any recoveries are made from any accounts previously written off, they are recognized as an offset to credit loss expense in the year of recovery. The total amount of write-offs was immaterial to the consolidated financial statements as a whole for the three and six months ended June 30, 2024.

The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible.

The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods:

Direct Customers—The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is low based on the Company’s historical experience. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts.

Distributors/Strategic Partners—The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Company’s historical experience. The estimate of expected credit losses considers the past payment history of each distributor.

Table of Contents

U.S. Government— These receivables are related to the Company’s government grants. The Company measures expected credit losses on these receivables using an individual reserve methodology. The risk of loss in this portfolio is very low based on the Company’s historical experience, as these receivables are supported by approved grant award contracts.

Inventories

Inventories are valued at the lower of cost or net realizable value under the first in, first out (FIFO) method. At June 30, 2024 and December 31, 2023, the Company’s inventory was comprised of finished goods, which amounted to $2,459,604 and $2,155,457, respectively; work in process, which amounted to $1,048,360 and $838,871, respectively; and raw materials, which amounted to $808,788 and $685,801, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use. Donated devices are removed from inventory and charged to selling, general and administrative expenses.

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the consolidated statements of operations and comprehensive loss in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.

Patents

Legal costs incurred to establish and successfully defend patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.

Impairment or Disposal of Long-Lived Assets

The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the three months ended June 30, 2024 and 2023, the Company recorded impairment charges of approximately $185,000 and $21,000, respectively, and during the six months ended June 30, 2024 and 2023, the Company recorded impairment charges of approximately $250,000 and $293,000, respectively, related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions and the abandonment of certain pending patent application costs in the ordinary course of business. This charge is included in legal, financial and other consulting in the consolidated statements of operations and comprehensive loss.

Revenue Recognition

Revenue is recognized when the Company ships its products to its direct customers and distributors/strategic partners. Revenue is recognized on its grant awards with agencies of U.S. government in accordance with the terms of the award contract. See Note 4 for a description of the types of government contracts. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for the products shipped or the services provided under their grant contracts. To achieve this core principle, the Company applies the following five steps:

Identify Contracts with Customers - The Company’s contracts with its direct customers are generally in the form of a purchase order. The Company has formal written contracts with each of its distributors/strategic partners that define their respective territories and minimum purchase commitments which must be met in order to maintain exclusivity in their territory. Distributors/strategic partner customers also submit purchase orders with each order that define the terms of shipment and transaction price. The Company has a contract for each grant award with various agencies of the U.S. government.

Table of Contents

Identify Performance Obligations - The performance obligations in contracts with direct customers and distributors/strategic partners are for the shipment of the CytoSorb device and related accessory parts. The performance obligations for government contracts are dependent on the contract type, however, these are generally based on the costs incurred related to each government contract.

Determine Transaction Price - The price charged is based on the Company’s price list for the CytoSorb device and related accessory parts for both direct customers and distributor/strategic partners. The Company does not permit returns for product sales. The Company also provides for certain rebates and discounts to direct customers for sales of its product that are earned based upon sales volume. These amounts, which are earned based on calendar year sales volume, are recorded as a reduction of sales as earned. The transaction prices for government contracts are dependent on the type of contract and are outlined in each contract.

Allocate Transaction Price to Performance Obligations - The transaction price for the performance obligation is based on the purchase orders received for both direct customers and on the type of contract and are outlined in each contract. The transaction prices for government contract performance obligations are dependent on the type of contract and are generally based on costs incurred.

Recognize Revenue as Performance Obligations are Satisfied - The Company satisfies its performance obligation to direct customers and distributors/strategic partners generally upon shipment of the products. The Company satisfies its performance obligations on government contracts generally upon incurring costs on each contract. The Company records deferred revenue related to fixed price government contracts to the extent that billings exceed costs incurred.

Research and Development and Clinical Trial Expenses

All research and development costs, payments to laboratories and research consultants are expensed when incurred.

Advertising Expenses

Advertising expenses are included in selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss when incurred. Advertising expenses amounted to approximately $93,000 and $38,000 for the three months ended June 30, 2024 and 2023, respectively, and approximately $138,000 and $93,000 for the six months ended June 30, 2024 and 2023, respectively.

Income Taxes

Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the previously completed reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership. In 2017, the Tax Cuts and Jobs Act reduced the U.S. federal corporate tax rate from 35% to 21%.

The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at June 30, 2024. The Company is accounting for an uncertain tax position of approximately $2.1 million for the year ended December 31, 2023. The Company files tax returns in the U.S. federal and state jurisdictions.

The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company.

CytoSorbents Europe GmbH, CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents UK Limited, CytoSorbents Medical UK Limited, CytoSorbents India Private Limited and CytoSorbents France SAS file an annual corporate tax return, a VAT return and a trade tax return in Germany, Switzerland, Poland, France, the United Kingdom and India, respectively.

Table of Contents

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for credit losses and recoverability of patents are significant estimates in these consolidated financial statements.

Concentration of Credit Risk

The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”). Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured Cash Sweep (“ICS”) account whereby all cash that was previously held in the Company’s money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFi’s 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.

A significant portion of the Company’s revenues are from product sales in Germany. Substantially all of the Company’s grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Company’s revenue.)

As of June 30, 2024, two distributors accounted for approximately 30% of outstanding grants and accounts receivable. As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivable. For the three and six months ended June 30, 2024, one distributor accounted for approximately 14% and 12% of the Company’s total revenue. For the three months and six months ended June 30, 2023, one distributor accounted for approximately 12% and 11%, respectively, of the Company’s total revenue.

Financial Instruments

The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 “Distinguishing Liabilities From Equity” (“ASC 480”) and ASC 815 “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance, and will remain as a component of equity thereafter. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.

The warrants issued upon the closing of the Company’s December 13, 2023 Offering and the closing of the Company’s June 2024 debt financing both met the criteria for equity classification under ASC 815. Accordingly, these warrants have been classified as equity as of June 30, 2024 and December 31, 2023.

Table of Contents

Net Loss Per Common Share

Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed using the treasury stock method utilizing the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding stock options and restricted shares. The computation of diluted loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (see Note 8).

Stock-Based Compensation

The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation, for employees and directors, whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.

The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.

Shipping and Handling Costs

The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $64,000 and $122,000, respectively, for the three months ended June 30, 2024 and 2023, and $178,000 and $200,000, respectively, for the six months ended June 30, 2024 and 2023.

Effect of Recent Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”). ASU2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company adopted the provisions of ASU 2020-06 on January 1, 2024. This did not have a material impact on the Company’s financial statements.

In December 2023, the FASB issued ASU No. 2023-09 entitled “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This ASU provides guidance related to additional disclosures that will be required related to income taxes. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2024. This ASU will result in additional disclosures in the Company’s consolidated financial statements related to income taxes in 2025.

In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Improvements to Reportable Segment Disclosures. The guidance primarily will require enhanced disclosures about significant segment expenses. All disclosure requirements under ASU 2023-07 and existing segment disclosures in ASC 280, Segment Reporting are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A retrospective approach is required to be applied to all prior periods presented in the financial statements. The Company plans to adopt the provisions of ASU 2023-07 in the fourth quarter of fiscal 2024 and continues to evaluate the disclosure requirements related to the new standard.

Table of Contents

3. STOCKHOLDERS’ EQUITY

Preferred Stock

In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to 5,000,000 shares of “blank check” preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors.

Common Stock

In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from 50,000,000 shares to 100,000,000 shares.

Shelf Registration

On July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the “2021 Shelf”). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million and expires after three years. On July 26, 2024, the Company filed a registration statement on Form S-3 with the SEC (the “2024 Shelf”), which enables the Company to offer and sell in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million. The SEC has not yet declared the 2024 Shelf to be effective, however, the Company continues to be able to utilize the 2021 Shelf to offer securities. Because of the Company’s market capitalization is less than $75 million, it will be subject to baby shelf rules which limit the amount of securities sales the Company can make to one-third of its public market float over a 12-month period.

Open Market Sale Agreement with Jefferies LLC

On December 30, 2021, the Company entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock having an aggregate offering price of up to $25 million through the Agent, as the Company’s sales agent. All shares of the Company’s common stock offered and sold, or to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Company’s 2021 Shelf by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.

Subject to the terms of the Sales Agreement, the Agent is required to use its commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Company’s common stock from time to time, based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Company’s common stock sold thereunder, if any. There were no sales under the Sale Agreement during the year ended December 31, 2022. During the year ended December 31, 2023, the Company sold 2,656,464 shares pursuant to the Sale Agreement, at an average selling price of $1.76 per share, generating net proceeds of approximately $4,532,000. In addition, during the year ended December 31, 2023, the Company paid approximately $61,000 in expenses related to the Sale Agreement. During the six months ended June 30, 2024, the Company sold 53,290 shares pursuant to the Sales Agreement at an average selling price of $1.03 per share, generating net proceeds of approximately $53,000.

Stock-Based Compensation

Total share-based employee, director, and consultant compensation amounted to approximately $829,000 and $1,563,000 for the three and six months ended June 30, 2024, respectively, and approximately $570,000 and $1,401,000 for the three and six months ended June 30, 2023, respectively. These amounts are included in the consolidated statements of operations and comprehensive loss under selling, general, and administrative expenses.

Table of Contents

The summary of the stock option activity for the six months ended June 30, 2024 is as follows:


				Weighted
		Weighted		Average
		Average		Remaining
		Exercise Price		Contractual
	Shares	per Share		Life (Years)
Outstanding, December 31, 2023	10,548,174	$	4.49	7.01
Granted	3,378,366	$	0.95	—
Forfeited	(906,166)	$	2.78	—
Expired	(545,536)	$	5.31	—
Exercised	—	$	—	—
Outstanding, June 30, 2024	12,474,838	$	3.62	7.40

The fair value of each stock option was estimated using the Black Scholes pricing model, which takes into account as of the grant date the exercise price (ranging from $0.84 to $0.99 per share) and expected life of the stock option (6 years), the current price of the underlying stock and its expected volatility (76.6%), expected dividends (0)% on the stock and the risk free interest rate (ranging from 3.86% to 4.65%) for the expected term of the stock option.

The intrinsic value is calculated as the difference between the market value of the shares as of June 30, 2024 of $0.703 and the exercise price of the shares.


Options Outstanding
	Number	Weighted		Weighted
Range of	Outstanding at	Average		Average	Aggregate
Exercise	June 30,	Exercise		Remaining	Intrinsic
Price	2024	Price		Life (Years)	Value
$0.84 - $13.20	12,474,838	$	3.62	7.4	$	—


Options Exercisable
Number	Weighted
Exercisable at	Average		Aggregate
June 30,	Exercise		Intrinsic
2024	Price		Value
5,385,858	$	5.91	$	—

The summary of the status of the Company’s non-vested options for the six months ended June 30, 2024 is as follows:


		Weighted
		Average
		Grant Date
	Shares	Fair Value

Non-vested, December 31, 2023	5,205,736	$	1.89
Granted	3,378,366	$	0.67
Forfeited	(906,166)	$	1.88
Vested	(588,956)	$	2.73
Non-vested, June 30, 2024	7,088,980	$	0.99

As of June 30, 2024, the Company had approximately $4,419,000 of total unrecognized compensation cost related to stock options which will be amortized over approximately 36 months.

On March 29, 2024, the Board of Directors granted options to purchase 380,480 shares of common stock to certain executive officers and certain other non-executive officer employees related to the Company’s salary reduction for stock options program. These options will vest in full on January 31, 2025. The grant date fair value of these unvested options amounted to approximately $249,000.

Table of Contents

On April 2, 2024, the Board of Directors granted options to purchase 1,214,400 shares of common stock to the Company’s employees which will be awarded based upon each employee’s 2024 individual performance evaluation. Once awarded, these options will vest one half on the first anniversary of the grant date, one quarter on the second anniversary of the grant date, and one quarter on the third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $830,000.

On April 2, 2024, the Board of Directors granted options to purchase 922,147 shares of common stock to certain of the Company’s employees. These options will vest in full on the first anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $594,000.

On April 2, 2024, the Board of Directors granted options to purchase 110,000 shares of common stock to members of the Company’s Board of Directors. These options will vest in full on the first anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $71,000.

On April 2, 2024, the Board of Directors granted options to purchase 556,000 shares of common stock to certain senior managers of the Company. These options will vest one half on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $380,000.

On April 8, 2024, the Board of Directors granted options to purchase 131,339 shares of common stock employees related to the Company’s salary reduction for stock options program. The grant date fair value of these unvested options amounted to approximately $85,000. These options will vest in full on January 31, 2025.

During the six months ended June 30, 2024, 64,000 options were awarded to newly hired employees and consultants in connection with their employment or consulting agreements.

Change in Control-Based Awards of Restricted Stock Units:

The Board of Directors has granted restricted stock units to members of the Board of Directors, to the Company’s executive officers, and to employees of the Company. These restricted stock units will only vest upon a Change in Control of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan.

The following table is a summary of these restricted stock units:


	Restricted Stock Units
	Board of	Executive	Other
	Directors	Management	Employees	Total	Intrinsic Value
December 31, 2023	346,500	779,500	1,697,500	2,823,500	$	3,134,085
Granted	—	—	156,250	156,250
Forfeited	—	—	(283,750)	(283,750)
June 30, 2024	346,500	779,500	1,570,000	2,696,000	$	1,926,044

Due to the uncertainty over whether these restricted stock units will vest, which only happens upon a Change in Control, no charge for these restricted stock units has been recorded in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023.

Other Awards of Restricted Stock Units:

On August 10, 2022, certain named executive officers and senior managers were granted 288,500 restricted stock units. These awards were valued at approximately $563,000 at the date of issuance, based upon the market price of the Company’s common stock at the date of the grant, and vested (or will vest) one-third on the date of the grant, one-third on the first anniversary of the date of the grant, and one-third on the second anniversary of the date of the grant. For the three and six months ended June 30, 2024, and 2023, the Company recorded a charge of approximately $47,000 and $94,000, and $47,000 and $94,000, respectively, related to these restricted stock unit awards.

Table of Contents

On July 7, 2023, certain named executive officers and senior managers were granted 250,000 restricted stock units. These awards were valued at approximately $883,000 at the date of issuance, based upon the market price of the Company’s common stock at the date of the grant, and will vest two-third on the first anniversary of date of the grant, and one-third on the second anniversary of the date of the grant. For the three and six months ended June 30, 2024, the Company recorded a charge of approximately $110,000 and $221,000, respectively, related to these restricted stock unit awards.

On September 18, 2023, a named executive officer was granted 45,000 restricted stock units. This award was valued at approximately $89,000 at the date of issuance, based upon the market price of the Company’s common stock at the date of the grant. These restricted stock units vested (will vest) as follows: 25,000 on the date of the grant, 10,000 on the first anniversary of the date of the grant and 10,000 on the second anniversary of the date of the grant. For the three and six months ended June 30, 2024, the Company recorded a charge of approximately $5,000 and $10,000, respectively, related to these restricted stock unit awards.

On April 2, 2024, the Board of Directors granted 343,000 restricted stock units to certain senior managers of the Company. These awards were valued at approximately $328,000 at the date of issuance, based upon the market price of the Company’s common stock at the date of the grant, and will vest one half on the first anniversary of the grant date and one half on the second anniversary of the grant date. For the three and six months ended June 30, 2024, the Company recorded a charge of approximately $40,000 and $40,000, respectively, related to these restricted stock unit awards.

Additionally, certain employees were offered a total of 103,000 restricted stock units as a condition of their employment. These awards were valued at approximately $410,000 at the date of issuance. 40,000 of the restricted stock units valued at $149,000 were forfeited in Q2 2024. 20,000 of the restricted stock units valued at $132,000 were vested in Q2 2024. 13,000 of these restricted stock units vest upon the earlier of a Change in Control or one-third after the second anniversary of the award, one-third on the third anniversary of the award, and one-third on the fourth anniversary of the award. The other 30,000 of these restricted stock units vest upon the earlier of a Change in Control or three years from the date of the award. For the three and six months ended June 30, 2024, and 2023, the Company recorded a charge (income) of approximately $(191,000) and $(163,000), and $19,000 and $46,000, respectively, related to these restricted stock unit awards.

The following table outlines the restricted stock unit activity for the six months ended June 30, 2024:


		Weighted
		Average
		Grant Date
	Shares	Fair Value
Non-vested, December 31, 2023	430,505	$	3.31
Granted	373,000	$	0.96
Vested	(20,000)	$	6.59
Forfeited	(40,000)	$	3.73
Non-vested, June 30, 2024	743,505	$	2.02

Warrants:

As of June 30, 2024, the Company had 4,352,130 warrants outstanding. 2,706,561 warrants outstanding are related to the Company’s December 13, 2023 Offering and these warrants are immediately cash exercisable at an exercise price of $2.00 per share and expire on December 13, 2028. Another 1,645,569 warrants were issued on June 28, 2024 in connection with the Company’s Loan and Security Agreement with Avenue and these warrants have an exercise price of $0.79 and expire on June 28, 2029. The number of warrants is fixed, however, the exercise price may be adjusted down if the Company raises equity (excluding sales of equity utilizing the Company’s at-the-market equity facility) at a share price that is lower than $0.79. These warrants are excisable into common stock.

Table of Contents

4. REVENUE

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended June 30, 2024:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	20,398	$	18,000	$	—	$	38,398
Germany		2,778,594		—		—		2,778,594
All other countries		1,673,812		4,350,985		—		6,024,797
Total product revenue		4,472,804		4,368,985		—		8,841,789
Grant and other income:
United States		—		—		1,052,847		1,052,847

Total revenue	$	4,472,804	$	4,368,985	$	1,052,847	$	9,894,636

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended June 30, 2023:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	6,583	$	—	$	—	$	6,583
Germany		3,168,448		—		—		3,168,448
All other countries		1,493,725		3,403,656		—		4,897,381
Total product revenue		4,668,756		3,403,656		—		8,072,412
Grant and other income:
United States		—		—		1,348,409		1,348,409

Total revenue	$	4,668,756	$	3,403,656	$	1,348,409	$	9,420,821

The following table disaggregates the Company’s revenue by customer type and geographic area for the six months ended June 30, 2024:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	42,014	$	36,000	$	—	$	78,014
Germany		6,316,321		—		—		6,316,321
All other countries		3,424,353		8,012,621		—		11,436,974
Total product revenue		9,782,688		8,048,621		—		17,831,309
Grant and other income:
United States		—		—		1,849,619		1,849,619

Total revenue	$	9,782,688	$	8,048,621	$	1,849,619	$	19,680,928

Table of Contents

The following table disaggregates the Company’s revenue by customer type and geographic area for the six months ended June 30, 2023:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	10,353	$	—	$	—	$	10,353
Germany		6,506,352		—		—		6,506,352
All other countries		2,996,324		6,469,422		—		9,465,746
Total product revenue		9,513,029		6,469,422		—		15,982,451
Grant and other income:
United States		—		—		2,887,866		2,887,866

Total revenue	$	9,513,029	$	6,469,422	$	2,887,866	$	18,870,317

The Company has two primary revenue streams: (1) sales of the CytoSorb device and related device accessories and (2) grant income from contracts with various agencies of the United States government. The following is a brief description of each revenue stream.

CytoSorb Sales

The Company sells its CytoSorb device using both its own sales force (direct sales) and through the use of distributors and/or strategic partners. The majority of sales of the device are outside the United States, as CytoSorb is not yet approved for commercial sale in the United States. However, in April 2020, the Company was granted EUA of CytoSorb for use in critically-ill patients infected with COVID-19 with imminent or confirmed respiratory failure by the FDA. Direct sales outside the United States relate to sales to hospitals located in Germany, Switzerland, Austria, Belgium, Luxembourg, Poland, the Netherlands, Sweden, Denmark, Norway and the United Kingdom. Direct sales are fulfilled from the Company’s warehouse facility in Berlin, Germany. There are no formal sales contracts with any direct customers relating to product price or minimum purchase requirements. However, there are agreements in place with certain direct customers that provide for either free of charge product or rebate credits based upon achieving minimum purchase levels. The Company records the value of these items earned as a reduction of revenue. These customers submit purchase orders and the order is fulfilled and shipped directly to the customer. Prices to all direct customers are based on a standard price list based on the packaged quantity (6 packs versus 12 packs).

Distributor and strategic partner sales make up the remaining product sales. These distributors are located in various countries throughout the world. The Company has a formal written contract with each distributor/strategic partner. These contracts have terms ranging from 1-5 years in length, with three years being the typical term. In addition, certain distributors are eligible for volume discount pricing if their unit sales are in excess of the base amount in the contract.

Most distributor’s/strategic partner’s contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories.

There is no additional consideration or monetary penalty that would be required to be paid to CytoSorbents if a distributor does not meet the minimum purchase commitments included in the contract, however, at the discretion of the Company, the distributor may lose its exclusive rights in the territory if such commitments are not met.

Government Grants

The Company has been the recipient of various grant contracts from various agencies of the United States government, primarily the Department of Defense, to perform various research and development activities. These contracts fall into one of the following categories:

Fixed price – the Company invoices the contract amount in equal installments over the term of the contract without regard to the timing of the costs incurred related to this contract. If billings on fixed price contracts exceed the costs incurred, revenue will be deferred to the extent of the excess billings.

Table of Contents

Cost reimbursement – the Company submits monthly invoices during the term of the contract for the amount of direct costs incurred during that month plus an agreed upon percentage that relates to allowable overhead and general and administrative expenses. Cumulative amounts invoiced may not exceed the maximum amount of funding stipulated in the contract.

Cost plus – this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.

Performance based – the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.

These government contracts have terms ranging from three months to four years. The Company may apply for an extension of the term of the contract in order to complete its research and development activities but would not receive additional funding during the extension period in excess of the original contract. See Note 2 regarding the accounting policies related to these contracts.

In summary, the contracts the Company has with customers are the distributor/strategic partner contracts related to CytoSorb product sales, agreements with direct customers related to free-of-charge product and credit rebates based upon achieving minimum purchase levels, and contracts with various government agencies related to the Company’s grants. The Company does not currently incur any outside/third party incremental costs to obtain any of these contracts. The Company does incur internal costs, primarily salary related costs, to obtain the contracts related to the grants. Company employees spend time reviewing the program requirements and developing the budget and related proposal to submit to the grantor agency. There may additionally be travel expenditures involved with meeting with government agency officials during the negotiation of the contract. These internal costs are expensed as incurred.

The following table provides information about receivables and contract liabilities from contracts with customers:


	June 30, 2024		December 31, 2023
Receivables, which are included in grants and accounts receivable	$	5,906,808	$	3,846,271
Contract liabilities, which are included in accrued expenses and other current liabilities	$	1,298,050	$	1,573,141

Contract receivables represent balances due from product sales to distributors amounting to $5,424,751 and $3,270,724 at June 30, 2024 and December 31, 2023, respectively, and billed and unbilled amounts due on government contracts amounting to $482,057 and $575,547 at June 30, 2024 and December 31, 2023, respectively.

Contract liabilities represent the value of free of charge goods and credit rebates earned in accordance with the terms of certain direct customer agreements, which amounted to $201,887 and $196,322 as of June 30, 2024 and December 31, 2023, respectively, and deferred grant revenue related to the billing on fixed price contracts in excess of costs incurred, which amounted to $1,096,163 and $1,376,819 at June 30, 2024 and December 31, 2023, respectively.

5. LONG-TERM DEBT, NET

Avenue Capital Group:

On June 28, 2024 (the “Closing Date”), the Company entered into a Loan and Security Agreement (as amended, supplemented, restated or otherwise modified as of the date hereof and from time to time, the “Loan and Security Agreement”) with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue”), Avenue Venture Opportunities Fund II, L.P., a Delaware limited partnership (“Avenue 2” and, together with Avenue, the “Lenders”), and Avenue Capital Management II, L.P., a Delaware limited partnership (the “Administrative and Collateral Agent”).

Under the Loan and Security Agreement, the Lenders have agreed to loan to the Company up to an aggregate of $20 million, to be disbursed in two tranches: (1) one tranche of $15 million (“Growth Capital Loan Tranche 1”) on the Closing Date, with $4.5 million funded by Avenue and $10.5 million funded by Avenue 2, of which $10 million is available to the Company on the Closing Date and $5 million constitutes restricted cash subject to release to the Company prior to March 31, 2025, provided (i) the FDA has accepted Company’s application for review with respect to DrugSorb-ATR De Novo 510(k) and (ii) the Company has received a minimum of $3 million in net proceeds from the sale of its equity securities after the Closing Date. The restriction will be released on a dollar for dollar

Table of Contents

basis for equity raised between $3 million and $5 million and (2) a second tranche of up to $5 million, which may be disbursed at the Company’s request between July 1, 2025 and December 31, 2025, provided that the Company receives FDA marketing approval of its DrugSorb-ATR application (“Growth Capital Loan Tranche 2” and together with Growth Capital Loan Tranche 1, the “Growth Capital Loans” or the “Commitment”). The proceeds from the Commitment were used to pay off the existing outstanding debt with Bridge Bank, and will additionally be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Each Growth Capital Loan shall bear interest at a variable rate per annum equal to the greater of (A) the Prime Rate (as defined in the Loan and Security Agreement) plus five percent (5.00%) or (B) thirteen and one-half percent (13.50%).

Commencing on August 1, 2024, the Company shall make monthly payments during the term of each Growth Capital Loan of interest only during the initial 25-month period following the Closing Date (as may be extended to the 30 months anniversary of the Closing Date upon satisfaction of certain conditions) and thereafter to maturity in equal monthly installments of principal plus accrued and unpaid interest. All unpaid principal and accrued and unpaid interest shall be due and payable in full on July 1, 2027; provided, however that if the Company draws the full amount of Growth Capital Loan Tranche 2 by December 2025, all unpaid principal and accrued and unpaid interest shall be due and payable in full by January 1, 2028. In addition, the Loan and Security Agreement required the Company to pay a non-refundable commitment fee equal to 1.00% of the Commitment due and payable on the Closing Date. In addition to the non-refundable commitment fee, the Company also paid financial advisor fees and legal fees of approximately $640,000 related to the Commitment. These costs are being amortized over the loan period as a charge to interest expense. During the three and six months ended June 30, 2024, the Company recorded interest expense of approximately $2,000 related to these costs. In addition, the Loan and Security Agreement requires the Company to pay a non-refundable final payment equal to 4.5% of the original commitment amount. This final payment has been accrued and included as part of the debt discount. This discount will be charged to interest expense over the term of the loan. For the three and six months ended June 30, 2024, the Company recorded interest expense of approximately $2,500 related to the debt discount.

The Capital Growth Loans are evidenced by secured promissory notes issued to the Lenders by the Company. If the Company elects to prepay the Growth Capital Loan(s) pursuant to the terms of the Loan and Security Agreement, it will owe a prepayment fee to the Lenders, as follows: (1) for a prepayment made on or after the funding date of a Growth Capital Loan through and including the first anniversary of such funding date, an amount equal to 3.00% of the principal amount of such Growth Capital Loan prepaid; (2) for a prepayment made after the first anniversary of the funding date of a Growth Capital Loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such Growth Capital Loan prepaid; and (3) for a prepayment made any time after the second anniversary of the funding date of a Growth Capital Loan, an amount equal to 1.00% of the principal amount of such Growth Capital Loan prepaid.

Events of default which may cause repayment of the Commitment to be accelerated include, among other customary events of default, (1) non-payment of any obligation when due, (2) the failure to perform any obligation required under the Loan and Security Agreement and to cure such default within a reasonable time frame, (3) the occurrence of any circumstance that has a Material Adverse Effect (as defined in the Loan and Security Agreement), (4) default beyond any applicable grace period or cure under any other agreement involving the borrowing of money in excess of the Threshold Amount (as defined in the Loan and Security Agreement), (5) any judgment(s) singly or in the aggregate in excess of the Threshold Amount entered against the Company that remain unsatisfied, unvacated or unstayed for 15 days or more after entry thereof (to the extent not otherwise covered by independent third-party insurance), and (6) if the Company becomes insolvent or starts an insolvency proceeding or if an insolvency proceeding is brought by a third party against the Company and such proceeding is not dismissed or stayed within 45 days. The Loan and Security Agreement includes customary loan conditions, company representations and warranties, company affirmative covenants and company negative covenants for secured transactions of this type. As of June 30, 2024, the Company was in compliance with these covenants.

As additional consideration for the Commitment, on June 28, 2024, the Company also issued each Lender a warrant instrument (each, a “Warrant”) entitling the Lenders to purchase an aggregate of 1,645,569 shares of the Company’s common stock for cash at the exercise price of $0.79 and expire on June 28, 2029. The number of warrants is fixed, however, the exercise price may be adjusted down if the Company raises equity (excluding sales of equity utilizing the Company’s at-the-market equity facility) at a share price that is lower than $0.79. These warrants meet the criteria for equity classification under ASC 815. Accordingly, the Company has recorded a debt discount and additional paid in capital of approximately $690,000 related to these warrants as of June 30, 2024. This discount will be charged to interest expense over the term of the loan.

Table of Contents

The Lenders were also granted the right while the Commitment is outstanding to convert up to an aggregate amount of $2,000,000 of the principal amount of the outstanding Growth Capital Loans into the Company’s common stock at a fixed conversion price of 120% of the Closing Price (as defined in the warrant) or $0.95 per share (the “Conversion Option”).

The Company’s and CytoSorbents Medical’s obligations under the Loan and Security Agreement are joint and several. The obligations under the Loan and Security Agreement are secured by a first priority security interest in favor of the Lenders with respect to the Company’s Shares (as defined in the Loan and Security Agreement) and the Company’s Collateral (as defined in the Loan and Security Agreement), which includes the Company’s intellectual property, pursuant to that certain Intellectual Property Security Agreement, dated as of June 28, 2024, by and between the Company and the Administrative and Collateral Agent.

Long-term debt consists of the following as of June 30, 2024:


Principal amount	$	15,000,000
Accrued final fee		900,000
Less unamortized debt discount		(1,588,209)
Less unamortized debt acquisition costs		(638,596)
Subtotal		13,673,195
Less Current maturities		—
Long-term debt net of current maturities	$	13,673,195

Principal payments of long-term debt are due as follows during the periods ending June 30:


2025	$	—
2026		—
2027		13,750,000
2028		1,250,000
Total	$	15,000,000

Bridge Bank:

On June 28, 2024, concurrent with the closing of the Avenue financing discussed above, the Company paid off its existing outstanding debt with Bridge Bank. The following items survive the termination of the Bridge Bank Amended and Restated Loan and Security Agreement and related amendments:

2018 Success Fee Letter:

Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to 6.37% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the “Success Fee”) upon the first occurrence of any of the following events: (a) a sale or other disposition by the Borrower of all or substantially all of its assets; (b) a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrower’s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c) a transaction or a series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such “person” or “group” to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d) the closing price per share for the Company’s common stock on the Nasdaq Capital Market being the greater of (i) 70% or more over $7.05, the closing price of the Company’s common stock on March 29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for five successive business days, or (ii) at least 26.13% more than the average price of Company’s common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation terminated on the fifth anniversary of the funding of the Term B Loan which was July 31, 2024.

Table of Contents

2022 Success Fee Letter:

Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) 1% of $5 million if the Company draws down the first tranche of the Term C Loan and is payable only if the Company’s stock price equals or exceeds $8 for five consecutive trading days; (ii) 1.5% of $5 million if the Company draws down the second tranche of the Term C Loan and is payable only if the Company’s stock price equals or exceeds $10 for five consecutive trading days; and (iii) 2% of $5,000,000 if the Company draws down the third tranche of the Term C Loan and is payable only if the Company’s stock price equals or exceeds $12 for five consecutive trading days (together, the “Success Fee”). As of June 28, 2024, the Company had drawn down only the first tranche of the Term C Loan. Borrower may pay the Success Fee in cash or in shares of common stock, at Borrower’s sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is the fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans. The termination date of this Letter is December 27, 2027.

6. COMMITMENTS AND CONTINGENCIES

Employment Agreements

On July 30, 2019, CytoSorbents Corporation entered into amended and restated executive employment agreements with its principal executives, Dr. Phillip P. Chan, Chief Executive Officer, Vincent Capponi, President and Chief Operating Officer, and Kathleen P. Bloch, the Company’s former Chief Financial Officer. Each of the agreements has an initial term of three years and was retroactively effective as of January 1, 2019. On April 12, 2020, CytoSorbents Corporation entered into an executive employment agreement with Dr. Efthymios Deliargyris, who began employment as Chief Medical Officer on May 1, 2020, with an initial term that expired on December 31, 2021. After the expiration of the initial terms, the employment agreements will automatically renew for additional terms of one year unless either party provides written notice of non-renewal at least 60 days prior to a renewal. In January 2024, these employment agreements automatically renewed for an additional one year.

The foregoing employment agreements each provide for base salary and other customary benefits which include participation in group insurance plans, paid time off and reimbursement of certain business-related expenses, including travel and continuing educational expenses, as well as bonus and/or equity awards at the discretion of the Board of Directors. In addition, the agreements provide for certain termination benefits in the event of termination without “Cause” or voluntary termination of employment for “Good Reason”, as defined in each agreement. The agreements also provide for certain benefits in the event of a “Change of Control” of the Company, as defined in each agreement.

Effective March 31, 2023, Ms. Bloch retired from her role as Chief Financial Officer of the Company. Ms. Bloch’s employment agreement expired on March 31, 2023, upon her retirement from the Company. In connection with Ms. Bloch’s retirement, the Company and Ms. Bloch entered into a Consulting Agreement, dated as of March 31, 2023 (the “Consulting Agreement”), pursuant to which Ms. Bloch served as a consultant to the Company and as the Company’s Interim Chief Financial Officer. On September 18, 2023, the Company entered into a new Employment Agreement with Ms. Kathleen P. Bloch pursuant to which Ms. Bloch will continue to serve as the Company’s Chief Financial Officer. Ms. Bloch’s service under the Employment Agreement has replaced and terminated the Consulting Agreement disclosed above. The Employment Agreement provides for base salary and other customary benefits which include participation in group insurance plans, paid time off and reimbursement of certain business-related expenses, including travel and continuing educational expenses, as well as bonus and/or equity awards at the discretion of the Board of Directors. In addition, the agreement provides for certain termination benefits in the event of termination without “Cause” or voluntary termination of employment for “Good Reason”, as defined in each agreement. Unless terminated sooner by either the Company or Ms. Bloch, the Employment Agreement will remain in effect until December 31, 2025, and thereafter, as mutually agreed between the Company and Ms. Bloch.

Table of Contents

Litigation

The Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation.

On March 5, 2024, Danielle Greene, a former employee, filed a complaint against us in the Superior Court of New Jersey, Law Division, Mercer County, alleging breach of the New Jersey Conscientious Employee Protection Act (“CEPA”). The complaint specifically alleges that we violated the provisions of the CEPA by allegedly terminating Ms. Greene in retaliation for complaining about certain business practices. We dispute these allegations and intend to vigorously defend against them, but there can be no assurance as to the outcome of the litigation.

Royalty Agreements

Pursuant to an agreement dated August 11, 2003, an existing investor agreed to make a $4 million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement the Company granted the investor a perpetual royalty of 3% on all gross revenues received by the Company from the sale of its CytoSorb device which such rights were assigned to an existing investor in 2017. For the three months ended June 30, 2024 and 2023, the Company recorded royalty expenses of approximately $264,000 and $240,000, respectively. For the six months ended June 30, 2024 and 2023, the Company recorded royalty expenses of approximately $531,000 and $474,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.

On August 1, 2022, the Company entered into the Marketing Agreement with Fresenius, which expands the Company’s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the “Term”). To help support the increased marketing and promotional efforts of the expanded collaboration, the Company has agreed to subsidize a portion of the marketing costs through royalty payments to Fresenius. Initially, the Marketing Agreement provides for royalty payments equal to 0.9% of the Company’s net sales of CytoSorb products made during the Term (excluding net sales in the United States). This initial royalty rate was determined based on certain assumptions regarding the percentage of the Company’s sale of CytoSorb products that are used with the Fresenius critical care platforms in the intensive care unit outside of the United States but is subject to adjustment if the Company determines that the underlying assumptions have changed significantly. For the three and six months ended June 30, 2024 and 2023, the Company did not record any expense related to this agreement. The launch of this program is expected to occur in 2024.

License Agreement

In an agreement dated September 1, 2006, the Company entered into a license agreement which provides the Company the exclusive right to use its patented technology and proprietary know-how relating to adsorbent polymers for a period of 18 years. Under the terms of the agreement, the Company has agreed to pay license fees of 2.5% to 5% on the sale of certain of its products if and when those products are sold commercially for a term not greater than 18 years commencing with the first sale of such product. For the three months ended June 30, 2024 and 2023 per the terms of the license agreement, the Company recorded licensing expenses of approximately $352,000 and $320,000, respectively. For the six months ended June 30, 2024 and 2023 per the terms of the license agreement, the Company recorded licensing expenses of approximately $709,000 and $632,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.

Table of Contents

7. LEASES

The Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and lasted until September 30, 2021. The lease also contains two five-year renewal options; however, the Company has determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will last for 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Company’s share of the total building space (92.3%). The landlord will also provide an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,467,000 as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification (“ASC”) 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease liability of approximately $11.6 million, which represents the estimated present value of the lease payments at the commencement date discounted at the Company’s incremental borrowing rate of 9.8%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease.

In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases.

In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease liability at the estimated present value of the lease payments at the commencement date of approximately $594,000.

Right-Of-Use Asset and Lease Liability

The Company’s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include the renewal periods for both of the facilities in Germany and do not include the renewal periods for the United States facility. The discount rate used was the Company’s incremental borrowing rate, which is 9.8%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of- use asset and related lease liability is as follows:


	June 30,		December 31,
	2024		2023
Right-of-use asset	$	11,789,539	$	12,058,896

Total lease liability	$	13,092,792	$	13,270,295
Less current portion		(412,067)		(373,636)
Lease liability, net of current portion	$	12,680,725	$	12,896,659

Table of Contents

The maturities of the lease liabilities are as follows for the periods ending June 30:


2025	$	1,676,044
2026		1,715,575
2027		1,756,193
2028		1,797,927
2029		1,840,810
Thereafter		14,487,274
Total lease payments		23,273,823
Present value discount		(10,181,031)
Total	$	13,092,792

For the three months ended June 30, 2024 and 2023, operating cash flows paid in connection with operating leases amounted to approximately $566,000 and $466,000, respectively, and $1,137,000 and $1,099,000 ,respectively, for the six months ended June 30, 2024 and 2023, respectively.

As of June 30, 2024 and December 31, 2023, the weighted average remaining lease term was years 11.9 and 12.7 years, respectively.

8. NET LOSS PER SHARE

Basic loss per share and diluted loss per share for the three and six months ended June 30, 2024 and 2023 have been computed by dividing the net loss for each respective period by the weighted average number of shares outstanding during that period.

All outstanding warrants, options and restricted stock awards representing approximately 20,266,000 and 11,904,000 incremental shares at June 30, 2024 and 2023, respectively, have been excluded from the computation of diluted loss per share as they are anti-dilutive.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Notes Regarding Forward Looking Statements

This Quarterly report on Form 10-Q includes “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and our expectations of the effects of the COVID-19 pandemic and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements.

Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, as updated by any risks reported in our Quarterly Reports on Form 10-Q and in the press releases and other communications to stockholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Overview

We are a leader in the treatment of life-threatening conditions in the intensive care (“ICU”) and cardiac surgery using blood purification via our proprietary polymer adsorption technology. We have a number of products commercialized and in development based on this technology platform. Our flagship product, CytoSorb^®, is already commercialized, and is being used to reduce deadly uncontrolled inflammation and dangerous substances in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure, bleeding, and other potentially fatal complications. Organ failure is the cause of nearly half of all deaths in the ICU, with little to improve clinical outcome. CytoSorb is approved in the European Union (“EU”) as an effective extracorporeal cytokine absorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. These are conditions where the mortality is extremely high, yet few to no effective treatments exist. In May 2018, we received a label expansion for CytoSorb covering use of the device for the removal of bilirubin and myoglobin in the treatment of liver disease and trauma, respectively. In January 2020, we received CE-Mark label expansion for CytoSorb covering the use of the device for the removal of the anti-platelet agent, ticagrelor, in patients undergoing surgery requiring cardiopulmonary bypass. In April 2020, the FDA granted Breakthrough Device Designation to CytoSorb for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. In April 2020, we announced that the FDA has granted EUA of CytoSorb for use in critically ill patients with COVID-19 infection and respiratory failure. In May 2020, we received a CE-Mark label expansion for CytoSorb for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. In August 2021, the Company announced that it was granted a second Breakthrough Device Designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA to remove the direct oral anticoagulants, rivaroxaban and apixaban. The Company has completed its pivotal randomized, controlled clinical trial in the U.S. and Canada, called the STAR-T trial, evaluating the use of DrugSorb-ATR during cardiothoracic surgery to prevent or reduce perioperative bleeding complications in pursuit of FDA and Health Canada marketing approval. We believe that the safety and efficacy results of the STAR-T trial will support regulatory submissions expected in the third quarter of 2024 for marketing approval by the FDA and Health Canada.

CytoSorb is used during and after cardiac surgery to remove inflammatory mediators, such as cytokines, activated complement, and free hemoglobin that can lead to post-operative complications such as acute kidney injury, lung injury, shock, and stroke. We believe CytoSorb has the potential to be used in many other inflammatory conditions, including the treatment of autoimmune disease flares, cytokine release syndrome in cancer immunotherapy, and other applications in cancer, such as cancer cachexia. CytoSorb has been used globally in more than 248,000 human treatments to date in critical illnesses and in cardiac surgery. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA. CytoSorb has been used globally in more than 7,650 human treatments to date in COVID-19 patients. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

Table of Contents

CytoSorb was also granted a second FDA Breakthrough Device designation for the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery.

We are focusing on three key objectives that we believe are the key to driving sustainable, long-term growth:

•

Open the U.S. and Canadian markets by obtaining FDA and Health Canada marketing approval for DrugSorb™-ATR to reduce the perioperative bleeding risk caused by Brilinta® and in the future, potentially other blood thinning drugs, in patients undergoing cardiothoracic surgery (see Clinical Studies Update)

•

Grow core CytoSorb sales to profitability, driven by numerous internal initiatives (see Sales and Marketing Update)

•

Reduce cash burn and maintain tight control over expenses.

Our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The technology is protected by 22 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally. We have numerous other product candidates under development based upon this unique blood purification technology, including CytoSorb XL, K+ontrol, HemoDefend-RBC, HemoDefend-BGA, ContrastSorb, DrugSorb, DrugSorb-ATR and others.

Our proprietary polymer technologies form the basis of a broad technology portfolio. Some of our products and product candidates include:

•

CytoSorb — an extracorporeal hemoperfusion cartridge approved in the EU for cytokine, bilirubin, myoglobin, and antithrombotic drug removal, with the goal of reducing deadly inflammation and toxic substances that can cause serious complications such as bleeding, organ failure, and death.

•

DrugSorb-ATR — an investigational extracorporeal antithrombotic removal system based on the same polymer technology as CytoSorb that was evaluated in the U.S. and Canadian STAR-T pivotal randomized, controlled trial to reduce perioperative bleeding complications in patients undergoing cardiothoracic surgery while on the antithrombotic drug Brilinta®.

•

ECOS-300CY — an adsorption cartridge approved in the E.U. for use with ex vivo organ perfusion systems to remove cytokines and other inflammatory mediators in the organ perfusate, with the goal of maintaining or improving solid organ function prior to transplant and improving postoperative outcomes. In 2021, commercialization of PerSorb™ (a private label version of ECOS-300CY) and Aferetica’s PerLife™ ex vivo organ perfusion system commenced in Italy.

•

CytoSorb XL — an intended next generation successor to CytoSorb currently in advanced pre-clinical testing designed to reduce a broad range of cytokines and inflammatory mediators, including lipopolysaccharide endotoxin, from blood.

•

VetResQ — a broad spectrum blood purification adsorber designed to help treat deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, severe systemic inflammation, toxin-mediated diseases, pancreatitis, trauma, liver failure, and drug intoxication. VetResQ is being commercialized in the United States.

•

HemoDefend-RBC—a development-stage blood purification technology designed to remove non-infectious contaminants in blood transfusion products, with the goal of reducing transfusion reactions and improving the quality and safety of blood.

•

HemoDefend-BGA—a development-stage purification technology that can remove anti-A and anti-B antibodies from plasma and whole blood, to enable “universal plasma” and safer whole blood transfusions, respectively.

•

K⁺ontrol—a development-stage blood purification technology designed to reduce excessive levels of potassium in the blood that can be fatal in severe hyperkalemia.

Table of Contents

•

ContrastSorb—a development-stage extracorporeal hemoperfusion cartridge designed to remove IV contrast from the blood of high-risk patients undergoing radiological imaging with contrast, or interventional radiology procedures such as cardiac catheterization and angioplasty. The goal of ContrastSorb is to prevent contrast-induced nephropathy.

•

DrugSorb—a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood (e.g., drug overdose, high dose regional chemotherapy).

•

BetaSorb—a development-stage extracorporeal hemoperfusion cartridge designed to remove mid-molecular weight toxins, such as b2-microglobulin, that standard high-flux dialysis cannot remove effectively. The goal of BetaSorb is to improve the efficacy of dialysis or hemofiltration.

Clinical Studies Update

For a complete discussion regarding our clinical study history, please refer to the section entitled Clinical Studies included in Item 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 14, 2024. The following includes certain updates regarding these clinical studies subsequent to the filing of the Company’s Annual Report on Form 10-K.

In July 2021, we received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study in 120 patients entitled, “Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T),” in the United States to support FDA marketing approval. This was done under the previously announced FDA Breakthrough Device Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. In October 2021, the first patient was enrolled, with the STAR-T study actively recruiting at multiple U.S. sites. In November 2022, the first milestone was completed with the first one-third of patients enrolled, triggering the first Data and Safety Monitoring Board (DSMB) meeting. The DSMB recommended to continue the study as planned without any modifications. In 2022, we also received FDA approval to expand the study to Canada and subsequently received Health Canada approval allowing inclusion of Canadian sites into the STAR-T trial in January 2023. In early 2023, the study exceeded 50% enrollment and reached the 2nd milestone of 67% enrollment in the spring of 2023, triggering another DSMB safety review, which found no safety concerns and recommended completion of the trial. The study completed enrollment in July of 2023 triggering the final DSMB safety review following database lock in December 2023, which also reported no safety concerns thereby meeting the primary safety endpoint of the study. Based on the initial analysis of the STAR-T data, the study did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries. However, the study did demonstrate evidence of reduced bleeding complications, including serious bleeding events, in patients in the pre-specified isolated coronary artery bypass graft (“CABG”) surgery population. Patients undergoing CABG surgery represented more than 90% of the overall study population. The topline results of 140-patient, double-blinded, multicenter, pivotal STAR-T randomized, controlled trial were presented as a late breaking presentation at the 104th Annual Meeting of the American Association for Thoracic Surgery (AATS) held in Toronto, Canada on April 28, 2024. The Company believes the safety and effectiveness data from STAR-T will support the parallel regulatory submission of DrugSorb-ATR to the FDA and Health Canada estimated to be filed in the third quarter of 2024.

In October 2021, we also received FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, “Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D),” in the United States to support FDA marketing approval. This was done under the previously announced 2nd FDA Breakthrough Device Designation granted for our DrugSorb-ATR Antithrombotic Removal System. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. The STAR-D study was postponed to allow the Company to concentrate its clinical focus on STAR-T activities and associated regulatory filings.

In January 2020, CytoSorb received European Union CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received European Union CE Mark label expansion to include rivaroxaban removal for the same indication. The international Safe and Timely Antithrombotic Removal (STAR) Registry is designed to capture real world clinical and health economic outcomes with intraoperative antithrombotic drug removal. The Registry is actively recruiting in the U.K., Germany, Austria, Belgium and Sweden and is planned to expand to additional countries in 2024. Data outputs from the STAR Registry have already been reported at the EuroPCR 2023 conference in Paris in May 2023 and at the European Association of Cardiothoracic Surgery conference in Vienna in October 2023. The Registry has been enrolling

Table of Contents

well and reported an updated analysis on ticagrelor removal during CABG at the 2024 EuroPCR conference. An additional updated analysis on DOAC removal has been accepted for presentation at the upcoming 2024 EACTS conference. Interim analyses from the Registry were also published in May 2024 in the internationally recognized peer-review Journal of Thrombosis and Thrombolysis. Additional results from the STAR Registry will also be submitted for publication in major cardiovascular journals on a rolling basis as enrollment progresses.

In April 2020, we received FDA Emergency Use Authorization for the treatment of adult critically ill COVID-19 patients with confirmed or imminent respiratory failure. The U.S. CytoSorb Therapy in COVID-19 (CTC) Registry was launched to capture outcomes and device utilization patterns from multiple U.S. participating centers. Initial results on critically ill COVID-19 patients on extracorporeal membrane oxygenation (ECMO) treated with CytoSorb at participating U.S. centers showed high survival rates (73%) compared with the international benchmark Extracorporeal Life Support Organization (ELSO) Registry. The initial CTC results on the first 52 critically ill patients from five U.S. ECMO centers were presented at the International Symposium of Intensive Care Medicine conference in August 2021 in Brussels, Belgium, and published in the peer reviewed journal Frontiers in Medicine. The CTC registry completed enrollment with 100 patients from five centers, and the final results mirror the high survival (74%) seen in the previous analysis and have been published in the peer reviewed journal Critical Care. The data further demonstrate that earlier intervention with CytoSorb and ECMO was associated with shorter need for mechanical ventilation, ECMO, and ICU stay. These results lend support to our concept of “enhanced lung rest,” where ECMO helps the lungs rest by oxygenating blood extracorporeally and reducing the need for mechanical ventilation that can cause ventilator-induced lung injury, while CytoSorb reduces the circulating inflammatory mediators that cause continued capillary leak syndrome in the lungs. Together, the goal of this dual-therapy strategy is to give the lungs a chance to recover and heal, a pre-requisite for weaning off of mechanical ventilation and ECMO.

The German PROCYSS multicenter, randomized controlled trial evaluating the ability of CytoSorb to restore hemodynamic stability in patients with refractory septic shock is now currently enrolling. The speed of enrollment has been slower than anticipated, impacted by COVID-19 related institutional research staff shortages, decreased ICU bed capacity leading to fewer patients, and other factors.

The international COSMOS Registry was designed to capture real world outcomes and device utilization patterns across multiple critical care indications including but not limited to sepsis, acute respiratory failure, postoperative vasoplegia, acute liver failure, and acute pancreatitis. The Registry is actively enrolling in Spain, Germany and Italy with plans to expand in more countries in 2024. The intent of the Registry is to report outcomes at international conferences and submit the results for publication on a rolling basis as enrollment progresses. The first analysis of the Registry on the results in the first 100 patients enrolled was presented at the ISICEM meeting in Brussels in March 2024 and will also be submitted to a peer reviewed journal for publication.

Sales and Marketing Update

The following are the key initiatives that we have been executing upon to drive product sales growth in the future.

Near-term growth drivers

•

Driving Greater Usage from a Strong Customer Base: We had a 31% increase in active customers (defined as customers who purchased the device in the last 9 months) since the start of the pandemic through June 30, 2024. We continue to educate and train centers on how best to use our therapy, highlighting new clinical data and applications. We believe this is a core strategy that will help to drive near-term growth.

•

New Therapy Divisions: We have established three distinct therapy divisions within our commercial operations including Critical Care, Cardiovascular, and Liver/Kidney/other to develop these markets internationally with the focus of leaders with area-specific medical and commercial expertise, who work closely with our sales teams to best serve the needs and interests of our customers. The increased therapy area focus has already yielded good international sales momentum in many different areas, such as the use of CytoSorb in endocarditis and antithrombotic drug removal in cardiac surgery, in the treatment of liver disease, and in other critical care applications such as sepsis. We believe this infrastructure will yield similar successes across a broad array of applications.

•

Strategic Partnerships: We have entered into a global marketing agreement with Fresenius Medical Care, the largest dialysis company in the world, where CytoSorb has become the “featured solution for cytokine, bilirubin, and myoglobin removal” on its critical care platform of machines worldwide, with the exception of the U.S. Together, we are working to

Table of Contents

“Expand the Dimension of Blood Purification^®” in hospitals and to promote and market our respective kidney and liver replacement therapies around the world.

•

New Exclusive Private Hospital Chain Partnerships: We are now the preferred supplier of hemoadsorption technology to the three largest private hospital chains in Germany, including Asklepios Kliniken GmbH, and the former hospitals of RHÖN-KLINIKUM AG. Many of these hospitals are already current customers and our agreements facilitate access and sales of CytoSorb to these and all other relevant institutions within these hospital networks.

•

Rise of Existing and New Applications: Among the many applications, we highlight:

o

Shock: Many studies have highlighted the ability of CytoSorb to remove inflammatory mediators and help to stabilize shock, a potentially fatal drop in blood pressure, in a wide range of patients. A recent 2019 meta-analysis, found that approximately 10% of ICU patients have septic shock at admission and 8% of patients admitted to the ICU have septic shock at some point in their hospital stay, with a high mortality of 38%. CytoSorb is being used around the world as a treatment of shock and we are conducting the PROCYSS RCT to formally evaluate CytoSorb as a treatment of this common and major unmet medical need.

o

Liver disease: In the treatment of acute liver disease, CytoSorb outperforms the market leading MARS® platform (Baxter) in the ex vivo removal of many liver toxins, but has the added benefit of removing cytokines and inflammatory mediators, while being much easier to use. In real-world practice, CytoSorb has replaced MARS at many accounts.

o

Lung Injury: Our U.S. CTC registry publication in Critical Care highlights the high survival of critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) treated with CytoSorb and ECMO under FDA Emergency Use Authorization. We believe these data demonstrate a therapeutic strategy of “enhanced lung rest” using the combined therapies that can be extrapolated to the treatment of ARDS in non-COVID patients, a very large market.

Longer-term growth drivers

•

Stand-alone blood pump strategy: There are many applications where a simple, low-cost hemoperfusion pump is adequate to implement our CytoSorb blood purification technology, without the complexity of a large dialysis or continuous renal replacement therapy (CRRT) machine, without the need for a dialysis technician, and where patients do not need to have failed kidneys. This would greatly simplify treatment with CytoSorb in the ICU - potentially enabling its more ubiquitous and earlier use on more patients while opening the door for more new applications in the emergency room, surgery suites, and elsewhere, in what we call the “hospital-wide” application. In June 2024, the Company announced the launch and immediate availability of its PuriFi™ hemoperfusion machine in the EU, following approval and certification under the EU Medical Device Regulation (MDR). The combination of CytoSorb with the PuriFi pump is expected to be an excellent combination treatment and a potentially game-changing new business model going forward.

•

Expansion of direct sales territories: Although opening new countries with a direct sales force requires time, cost, and effort, it also allows us to directly lead the effort, drive results, and benefit from more profitable sales. With the announcement of expansion of direct sales into the U.K., Ireland and France, we now sell direct in three of the E.U.’s Big 5 Economies - Germany, France and the U.K. - and a total of 15 countries direct overall, while working with distributors or partners in 60 other countries, including the other two Big 5 Economies: Italy, and Spain.

•

Investment in important clinical studies in shock, liver failure, cardiac surgery, ATR, etc.: We are committed to funding Company-sponsored studies in key areas that we believe will drive international adoption and usage, with the goal of becoming a standard of care for those applications.

Table of Contents

•

New Products: Over the past couple of years, there has been increasing momentum around two additional marketed products, ECOS-300CY for ex vivo organ perfusion (EVOP) in solid organ transplant under the EU CE mark, and VetResQ in the U.S. for the treatment of companion animals. In particular, prominent research in the field of heart, lung and liver organ transplant highlight the benefits of our technology in controlling inflammation and improving organ function during EVOP.

COVID-19 Business Update

COVID-19 patients develop life-threatening complications such as acute respiratory distress syndrome (ARDS), shock (i.e. a potentially fatal drop in blood pressure), kidney failure, acute cardiac injury, thromboses and emboli, and secondary bacterial infections. The underlying cause for these complications is often a massive, systemic inflammatory response, leading to the damage of vital organs such as the lungs, heart, and kidneys, and ultimately multiple organ failure and death in many cases. Hypercoagulability, thought triggered by inflammation, and resulting thromboembolic events such as pulmonary emboli and thrombotic microangiopathy, play another critical role in the pathophysiology of COVID-19 infection and severity of illness.

The use of CytoSorb in patients infected with COVID-19 in Italy, China, Germany and France began in March 2020. During the pandemic, CytoSorb has been used to treat dangerous inflammation and related life-threatening complications in more than 7,650 COVID-19 patients in more than 30 countries. Based upon initial data and reports from physicians treating these complications, CytoSorb use has generally been associated with a marked reduction in cytokine storm and inflammation, improved lung function, weaning from mechanical ventilation, decannulation from extracorporeal membrane oxygenation (ECMO), and a reversal of shock.

The use of CytoSorb has not been approved in the U.S. by the FDA. However, under certain circumstances, investigational medical devices that have not yet been FDA-approved may be made available for emergency use in the U.S. under the FDA’s Expanded Access Program (“EAP”). On April 13, 2020, we announced that the FDA, in a different program than the EAP, granted U.S. Emergency Use Authorization (EUA) of CytoSorb for use in adult critically ill COVID-19 patients. Under the EUA, CytoSorbents was able to make CytoSorb available, through commercial sales, to all hospitals in the U.S. for use in patients, 18 years of age or older, with COVID-19 infection who are admitted to the intensive care unit with confirmed or imminent respiratory failure as a way to help treat acute lung injury or ARDS, severe disease, or life-threatening illness resulting in respiratory failure, septic shock, and/or multiple organ dysfunction or failure. The CytoSorb device has been authorized by FDA under an EUA. It has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA. With the advent of vaccines, anti-viral therapies, and natural immunity, the numbers of critically ill COVID patients and the severity of illness has dropped dramatically. We currently anticipate little to no COVID-19 related CytoSorb sales, though this could change depending on the circulating strains of coronavirus.

The U.S. CTC (CytoSorb Therapy in COVID-19) Registry was launched to capture outcomes and device utilization patterns from multiple U.S. participating centers treating critically ill COVID-19 patients according to the treatment recommendations of the FDA Emergency Use Authorization (EUA). Preliminary results on observed ICU mortality of COVID-19 patients with acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) and treated with CytoSorb according to FDA EUA criteria were presented at the International Symposium of Intensive Care Medicine conference in September 2021 in Brussels, Belgium. In December 2021 and published in the peer-reviewed journal Frontiers in Medicine. The CTC Registry has completed enrollment and the final results confirming high survival (74%) were presented at the European Society of Intensive Care Medicine conference October 2022 and also have been published in the prestigious peer-reviewed journal Critical Care.

Government Research Grants:

We have historically been successful in obtaining technology development contracts from governmental agencies such as the National Institutes of Health and the U.S. Department of Defense, including the Defense Advanced Research Projects Agency (“DARPA”), the U.S. Army, U.S. Special Operations Command (“USSOCOM”), the U.S. Air Force, Air Force Material Command (“USAF/AFMC”) and others. Currently, we have ongoing projects funded, in part, by the U.S. Army Medical Research Acquisition Activity (“USAMRAA”), the NHLBI, and the USAF/AFMC. For a complete discussion of the various research grants we have obtained, please refer to the section entitled Government Research Grants included in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 14, 2024.

Table of Contents

Research and Development Update

Our research and development work levels have returned back to pre-pandemic levels. As of June 30, 2024, the revenue remaining to be earned on open grant contracts is $3.9 million. Overall, grant funded programs, HemoDefend-BGA™ (Universal Plasma), HemoDefend-RBC™ and K⁺ontrol™, continue to progress and we have been the beneficiary of approximately $15.8 million, $4.7 million and $7.7 million in total funding, respectively, awarded to date.

Impact of Inflation and Other Issues:

The current high inflationary environment has impacted us in various ways. Due to the current competitive labor market and high inflation, our labor costs have risen significantly in order to attract and retain qualified employees throughout our organization. In addition, we have experienced raw material price increases primarily related to the oil-based chemicals used in the polymer manufacturing process as well additional requests for higher fuel surcharges from most suppliers. Rising energy costs, including electricity and fossil fuels, have also made it more expensive to support our operations, manufacturing, and commercial activities. We have also experienced increases in our transportation costs; however, we have been able to substantially mitigate these cost increases by implementing bulk shipping methods. In addition, we have been able to mitigate most supply chain issues that existed during the COVID-19 pandemic by ordering larger quantities of inventory as they were available. Inflationary pressures may continue to impact our product gross margins in the future.

Comparison for the three months ended June 30, 2024 and 2023:

Revenues:

Revenue from product sales was approximately $8,842,000 in the three months ended June 30, 2024, as compared to approximately $8,072,000 in the three months ended June 30, 2023, an increase of approximately $770,000, or 10%. Distributor sales increased approximately $965,000, or 28%. Direct sales decreased approximately $196,000, or 4%. In addition, as a result of the decrease in the average exchange rate of the Euro to the U.S. dollar, 2024 product sales were negatively impacted by approximately $104,000. For the three months ended June 30, 2024, the average exchange rate of the Euro to the U.S. dollar was $1.08 as compared to an average exchange rate of $1.09 for the three months ended June 30, 2023.

Grant income was approximately $1,053,000 for the three months ended June 30, 2024 as compared to approximately $1,348,000 for the three months ended June 30, 2023, a decrease of approximately $295,000, or 22%. This decrease was due to the completion of several grants during 2023.

Total revenues were approximately $9,895,000 for the three months ended June 30, 2024, as compared to total revenues of approximately $9,421,000 for the three months ended June 30, 2023, an increase of approximately $474,000, or 5%.

Cost of Revenues:

For the three months ended June 30, 2024 and 2023, cost of revenue was approximately $3,392,000 and $3,402,000, respectively, a decrease of approximately $10,000. Product cost of revenue was approximately $2,411,000 and $2,093,000, respectively, for the three months ended June 30, 2024 and 2023, an increase of approximately $318,000 due to increases in sales in 2024. Gross margins on devices and device accessories were approximately 75% for the three months ended June 30, 2024 as compared to approximately 74% for the three months ended June 30, 2023. This increase was due to the achievement of greater operating efficiencies in 2024, which was partially offset by an increase in the percentage of lower margin distributor sales to total sales during the three months ended June 30, 2024 as compared to the three months ended June 30, 2023.

Table of Contents

Research and Development Expenses:

For the three months ended June 30, 2024, research and development expenses were approximately $1,520,000, as compared to research and development expenses of approximately $3,669,000 for the three months ended June 30, 2023, a decrease of approximately $2,149,000. This decrease was due to a decrease in our clinical trial activities of approximately $1,842,000 related to the completion of the STAR-T clinical trial in December 2023. The three months ended June 30, 2023 included $70,000 of non-recurring start-up costs associated with our new facility which were not incurred in the three months ended June 30, 2024. Cost savings measures resulted in decreased research and development salaries of approximately $170,000, and decreased consulting and other spending of approximately $67,000 in the second quarter of 2024.

Legal, Financial and Other Consulting Expenses:

Legal, financial, and other consulting expenses were approximately $821,000 for the three months ended June 30, 2024, as compared to approximately $1,185,000 for the three months ended June 30, 2023, a decrease of approximately $364,000. This decrease was due to a decrease in legal fees of approximately $314,000 due to the settlement of a legal matter in 2023, a decrease in employment agency fees of approximately $121,000 and a decrease in accounting fees of approximately $43,000. These decreases were offset by an increase in consulting fees of approximately $114,000.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses were approximately $7,581,000 for the three months ended June 30, 2024, as compared to approximately $7,724,000 for the three months ending June 30, 2023, a decrease of approximately $143,000. This decrease was due to a decrease in salaries, commissions, and related costs of approximately $543,000, a decrease in selling and distribution costs of approximately $468,000, a decrease in fees, licenses and permits of approximately $50,000, a decrease in commercial insurance of approximately $32,000, and a decrease in travel and entertainment expenses of approximately $20,000. These decreases were offset by increased non-cash stock compensation expense of approximately $623,000, a reduction in grant spending reduced the overhead absorption benefit to selling, general and administrative expense by approximately $136,000, an increase in network maintenance costs of approximately $81,000, an increase in transfer agent fees of approximately $49,000, an increase in royalty expense of approximately $46,000, and an increase in other general and administrative expenses of approximately $65,000.

Gain (Loss) on Foreign Currency Transactions:

For the three months ended June 30, 2024, the loss on foreign currency transactions was approximately $544,000 as compared to a gain of approximately $415,000 for the three months ended June 30, 2023. The 2024 loss was directly related to the decrease in the spot exchange rate of the Euro to the U.S. dollar at June 30, 2024 as compared to March 31, 2024. The spot exchange rate of the Euro to the U.S. dollar was $1.07 per Euro at June 30, 2024, as compared to $1.08 per Euro at March 31, 2024. The 2023 gain was directly related to the increase in the spot exchange rate of the Euro to the U.S. dollar at June 30, 2023 as compared to March 31, 2023. The spot exchange rate of the Euro to the U.S. dollar was $1.09 per Euro at June 30, 2023, as compared to $1.08 per Euro at March 31, 2023.

Comparison for the six months ended June 30, 2023 and 2022:

Revenues:

Revenue from product sales was approximately $17,831,000 for the six months ended June 30, 2024, as compared to approximately $15,982,000 for the six months ended June 30, 2023, an increase of approximately $1,849,000, or 12%. Distributor sales increased by approximately $1,579,000, or 24%. Overall direct sales increased by approximately $270,000, or 3%. The change in the exchange rate of the Euro to U.S. dollar did not have a significant impact on product sales during the six months ended June 30, 2024.

Grant income was approximately $1,850,000 for the six months ended June 30, 2024 as compared to approximately $2,888,000 for the six months ended June 30, 2023, a decrease of approximately $1,038,000 or 36%. This decrease was due to the completion of several grants during 2023.

Total revenues were approximately $19,681,000 for the six months ended June 30, 2024, as compared to total revenues of approximately $18,870,000 for the six months ended June 30, 2023, an increase of approximately $811,000, or 4%.

Table of Contents

Cost of Revenues:

For the six months ended June 30, 2024 and 2023, cost of revenue was approximately $6,607,000 and $7,396,000, respectively, a decrease of approximately $789,000, primarily due to a reduction in the cost of revenue related to the Company’s grant related activities. Product cost of revenue was approximately $4,759,000 and $4,624,000, respectively, for the six months ended June 30, 2024 and 2023, an increase of approximately $135,000. Gross margins on devices and device accessories were approximately 74% for the six months ended June 30, 2024 compared to approximately 71% for the six months ended June 30, 2023. The increase in product gross margin is due primarily to greater efficiencies now being realized at our new manufacturing facility in Princeton, New Jersey.

Research and Development Expenses:

For the six months ended June 30, 2024, research and development expenses were approximately $3,768,000 as compared to research and development expenses of approximately $7,883,000 for the six months ended June 30, 2023, a decrease of approximately $4,115,000. This decrease was due to a decrease in costs associated with our clinical trial activities of approximately $2,753,000 related to the completion of the STAR-T clinical trial in December 2023. The six months ending June 30, 2023 included $919,000 of non-recurring start-up costs associated with our new facility which were not incurred in the six months ending June 30, 2024. Cost savings measures resulted in decreased research and development salaries of approximately $297,000, and decreased other spending of approximately $146,000 in 2024.

Legal, Financial and Other Consulting Expenses:

Legal, financial, and other consulting expenses were approximately $1,501,000 for the six months ended June 30, 2024, as compared to approximately $1,854,000 for the six months ended June 30, 2023. The decrease of approximately $353,000 was due to a decrease in legal fees of approximately $285,000 and a decrease in employment agency fees of approximately $178,000. These decreases were offset by an increase in consulting fees of approximately $108,000 and an increase in accounting and auditing fees of approximately $2,000.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses were approximately $16,148,000 for the six months ended June 30, 2024, as compared to $16,187,000 for the six months ended June 30, 2023, a decrease of approximately $39,000. This decrease was due to a decrease in salaries, commissions and related costs of approximately $721,000, a decrease in advertising costs of approximately $192,000, a decrease in non-recurring facility start-up costs of approximately $176,000, a decrease in occupancy costs of approximately $140,000 and a decrease in other general and administrative expenses of $17,000. These decreases were offset by an increase in non-cash stock compensation expense of approximately $467,000, a reduction in grant spending reduced the overhead absorption benefit to selling, general and administrative expense by approximately $350,000, an increase in royalty expense of approximately $134,000, an increase in travel and entertainment expenses of approximately $112,000, an increase in network maintenance costs of approximately $95,000 and an increase in transfer agent fees of approximately $49,000.

Gain (Loss) on Foreign Currency Transactions:

For the six months ended June 30, 2024, the loss on foreign currency transactions was approximately $1,970,000 as compared to a gain of approximately $1,076,000 for the six months ended June 30, 2023. The 2024 loss was directly related to the decrease in the spot exchange rate of the Euro to the U.S. dollar as of June 30, 2024 as compared to December 31, 2023. The spot exchange rate of the Euro to the U.S. dollar was $1.07 per Euro as of June 30, 2024, as compared to $1.11 per Euro at December 31, 2023. The 2023 gain was directly related to the increase in the spot exchange rate of the Euro to the U.S. dollar as of June 30, 2023 as compared to December 31, 2022. The spot exchange rate of the Euro to the U.S. dollar was $1.09 per Euro as of June 30, 2023, as compared to $1.07 per Euro at December 31, 2022.

Table of Contents

History of Operating Losses:

We have experienced substantial operating losses since inception. As of June 30, 2024, we had an accumulated deficit of approximately $293,006,000, which included losses of approximately $10,501,000 and $13,479,000 for the six-month periods ended June 30, 2024 and 2023, respectively. Historically, losses have resulted principally from costs incurred in the research and development of our polymer technology, clinical studies, and general and administrative expenses.

Liquidity and Capital Resources

Since inception, our operations have been primarily financed through the issuance of debt and equity securities. As of June 30, 2024, we had current assets of approximately $21,955,000 and current liabilities of approximately $10,336,000. As of June 30, 2024, $25 million of our total shelf amount was allocated to our ATM facility, of which approximately $20.3 million is still available. During the six months ended June 30, 2024, the Company sold 53,290 shares pursuant to the Sale Agreement, at an average selling price of $1.03 per share, generating net proceeds of approximately $53,200.

In June of 2024, we closed on a $20 million term-loan facility with Avenue Capital Group which provided an initial tranche of $15 million at the closing of which $10 million was immediately available at closing and $5 million constitutes restricted cash subject to release to the Company prior to March 31, 2025, provided certain conditions are met. Another tranche of $5 million may be disbursed at the Company’s request between July 1, 2025 and December 31, 2025, provided that the Company receives FDA marketing approval of its DrugSorb-ATR application. Concurrently with the closing of the first tranche, the Company paid off our existing debt with Bridge Bank.

In March of 2024, we received approximately $880,000 in cash from the approved sale of our net operating losses and research and development credits from the State of New Jersey.

We are also managing our resources proactively, continuing to invest in key areas such as our planned regulatory submission of DrugSorb-ATR to U.S. FDA and Health Canada. We have also instituted and continue to maintain tight control over expenditures.

As of June 30, 2024 we have approximately $14.9 million in cash, including approximately $8.4 million and $6.5 million in unrestricted and restricted cash, respectively. With our cost cutting efforts, we believe this is sufficient to fund the Company’s operations into the second quarter of 2025. The Company continues to pursue additional milestones related to its recently announced Avenue debt facility that would increase its unrestricted cash position by up to $10 million. If these milestones are not achieved, we will need to raise additional capital to support our ongoing operations in the future. Meanwhile the Company continues to evaluate other traditional and alternative sources of capital, including additional less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors.

COVID-19 Impact on Financial Results

For the first year and a half of the coronavirus pandemic, COVID-19 was generally a positive driver for CytoSorb sales and highlighted the use of CytoSorb to treat cytokine storm and hyperinflammation. Because of this, the pandemic was a catalyst for CytoSorb orders from existing customers and also from new hospitals in countries where CytoSorb was not previously sold. We believe this awareness of CytoSorb increased overall usage during the COVID-19 pandemic and may help to drive further CytoSorb sales in the future.

However, starting in the third quarter of 2021, the protracted COVID-19 pandemic began to have a negative impact on our business, due to pandemic-driven adverse market conditions worldwide, especially in Germany which is our largest market. The excessive workload in hospitals due to COVID has led to an exodus of healthcare workers from acute care worldwide, leaving hospitals short-staffed, particularly nursing. This in turn has forced the reduction in ICU beds and allowable patient censuses, and reduced the scheduling of revenue generating surgical procedures, resulting in decreased revenue and economic weakness at hospitals. Meanwhile, in 2022 the rates of severe COVID-19 illness requiring ICU care, and COVID-related death have been disproportionately very low. This is mainly attributed to high rates of vaccinations, natural immunity, and the availability of anti-viral drugs that are associated with reduced severity of illness, reduced need for hospitalization, and risk of death. These factors, in turn, have decreased the numbers of patients treatable with CytoSorb.

Table of Contents

Additionally, COVID slowed our ability to generate clinical data to support our sales and marketing efforts. Currently, we are seeing an easing of the of the negative impacts of COVID-19. In 2024, we have generally good access to hospitals and physicians which should positively impact our product sales in the future. The lessened impact of COVID-19 has also had a positive impact on patient enrollment of our clinical studies.

Contractual Obligations

In March 2021, the Company entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The commencement date of the lease was April 1, 2021. The Initial Early Term began on the commencement date (April 1, 2021) and lasted two months. The Early Term commenced on June 1, 2021 and lasted until September 30, 2021. The lease also contains two five-year renewal options. Commencing on September 30, 2021, the remaining lease term will last for 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement. In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021, multiplied by the Company’s share of the total building space (92.3%). The landlord also provided an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,334,000 as security.

In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021, requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031.

In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five year option to renew that would extend the lease term to August 31, 2031.

Off-balance Sheet Arrangements

We have no off-balance sheet arrangements.

Going Concern

Critical Accounting Policies and Estimates

A discussion of our critical accounting policies and estimates is contained in our Annual Report on Form 10-K.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Table of Contents

Item 4. Controls and Procedures.

We maintain disclosure controls and procedures designed to ensure information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosures. A controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

No change in our internal control over financial reporting occurred during the three and six months ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 14, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

Number		Description
31.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of Sarbanes Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of Sarbanes Oxley Act of 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
101		The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets at June 30, 2024 and December 31, 2023, (ii) Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three and six months ended June 30, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 and (v) Notes to Consolidated Financial Statements.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

** Portions of this exhibit identified by [***] have been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is private or confidential.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CYTOSORBENTS CORPORATION

Dated: August 13, 2024	By:	/s/ Phillip P. Chan
		Name: Phillip P. Chan
		Title: Chief Executive Officer
		(Principal Executive Officer)

Dated: August 13, 2024	By:	/s/ Kathleen P. Bloch
		Name: Kathleen P. Bloch, CPA
		Title: Chief Financial Officer
		(Principal Financial and Accounting Officer)

Exhibit 31.1

CERTIFICATION

OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Phillip Chan, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of CytoSorbents Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 13, 2024

/s/ Phillip P. Chan
Phillip P. Chan Principal Executive Officer

Exhibit 31.2

CERTIFICATION

OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Kathleen P. Bloch, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of CytoSorbents Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 13, 2024

/s/ Kathleen P. Bloch
Kathleen P. Bloch Principal Financial Officer

Exhibit 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Chan, Chief Executive Officer of CytoSorbents Corporation, hereby certify, that, to my knowledge:

1.	The Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in such Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of CytoSorbents Corporation.

Date: August 13, 2024

CYTOSORBENTS CORPORATION

By:	/s/ Phillip P. Chan
Phillip Chan
Chief Executive Officer

Exhibit 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Kathleen P. Bloch, the Chief Financial Officer of CytoSorbents Corporation, hereby certify, that, to my knowledge:

1.	The Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in such Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of CytoSorbents Corporation.

Date: August 13, 2024

CYTOSORBENTS CORPORATION

By:	/s/ Kathleen P. Bloch
Kathleen P. Bloch
Chief Financial Officer

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2024	Aug. 12, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-36792
Entity Registrant Name	CYTOSORBENTS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-0373793
Entity Address, Address Line One	305 College Road East
Entity Address, City or Town	Princeton,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	732
Local Phone Number	329-8885
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	CTSO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		54,429,617
Entity Central Index Key	0001175151
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 8,458,708	$ 14,131,137
Grants and accounts receivable, net of allowance of $88,017 as of June 30, 2024 and $49,663 at December 31, 2023	7,822,823	6,057,072
Inventories	4,316,752	3,680,129
Prepaid expenses and other current assets	1,357,017	1,834,485
Total current assets	21,955,300	25,702,823
Property and equipment, net	9,423,649	10,056,354
Restricted cash	6,483,958	1,483,958
Right-of-use assets	11,789,539	12,058,896
Other assets	3,774,345	3,958,603
Total Assets	53,426,791	53,260,634
Current Liabilities:
Accounts payable	3,047,038	3,802,170
Current maturities of long-term debt		2,500,000
Lease liability - current portion	412,067	373,636
Accrued expenses and other current liabilities	6,877,163	7,870,149
Total current liabilities	10,336,268	14,545,955
Lease liability, net of current portion	12,680,725	12,896,659
Long-term debt	13,673,195	2,542,857
Total Liabilities	36,690,188	29,985,471
Commitments and Contingencies (Note 6)
Stockholders' Equity:
Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023
Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,306,415 and 54,240,265 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	54,306	54,240
Additional paid-in capital	307,514,758	305,196,874
Accumulated other comprehensive income	2,173,818	529,321
Accumulated deficit	(293,006,279)	(282,505,272)
Total Stockholders' Equity	16,736,603	23,275,163
Total Liabilities and Stockholders' Equity	$ 53,426,791	$ 53,260,634

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
CONSOLIDATED BALANCE SHEETS
Grants and accounts receivable, net of allowance for doubtful accounts	$ 88,017	$ 49,663
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	54,306,415	54,240,265
Common Stock, shares outstanding	54,306,415	54,240,265

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue	$ 9,894,636	$ 9,420,821	$ 19,680,928	$ 18,870,317
Cost of revenue	3,391,907	3,402,271	6,607,621	7,396,440
Gross profit	6,502,729	6,018,550	13,073,307	11,473,877
Other expenses:
Research and development	1,519,618	3,668,804	3,767,811	7,883,219
Legal, financial and other consulting	820,732	1,185,031	1,501,437	1,854,264
Selling, general and administrative	7,581,201	7,723,952	16,148,400	16,187,226
Total expenses	9,921,551	12,577,787	21,417,648	25,924,709
Loss from operations	(3,418,822)	(6,559,237)	(8,344,341)	(14,450,832)
Other income (expense):
Interest income (expense), net	(180,098)	(8,821)	(186,750)	(71,992)
Gain (loss) on foreign currency transactions	(544,226)	414,974	(1,969,916)	1,075,656
Miscellaneous income (expense)				(31,799)
Total other income (expense), net	(724,324)	406,153	(2,156,666)	971,865
Loss before benefit from income taxes	(4,143,146)	(6,153,084)	(10,501,007)	(13,478,967)
Net loss attributable to common stockholders	$ (4,143,146)	$ (6,153,084)	$ (10,501,007)	$ (13,478,967)
Basic net loss per common share	$ (0.08)	$ (0.14)	$ (0.19)	$ (0.31)
Diluted net loss per common share	$ (0.08)	$ (0.14)	$ (0.19)	$ (0.31)
Weighted average number of shares of common stock outstanding, basic	54,306,041	44,015,380	54,284,416	43,758,888
Weighted average number of shares of common stock outstanding, diluted	54,306,041	44,015,380	54,284,416	43,758,888
Comprehensive loss:
Net loss	$ (4,143,146)	$ (6,153,084)	$ (10,501,007)	$ (13,478,967)
Other comprehensive income (loss):
Foreign currency translation adjustment	421,322	(392,674)	1,644,497	(1,000,882)
Comprehensive loss	(3,721,824)	(6,545,758)	(8,856,510)	(14,479,849)
Total product sales
Revenue:
Total revenue	8,841,789	8,072,412	17,831,309	15,982,451
CytoSorb sales
Revenue:
Total revenue	8,830,391	8,065,829	17,795,181	15,972,098
Other product sales
Revenue:
Total revenue	11,398	6,583	36,128	10,353
Grant income
Revenue:
Total revenue	$ 1,052,847	$ 1,348,409	$ 1,849,619	$ 2,887,866

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 43,635	$ 287,000,021	$ 2,329,195	$ (253,997,878)	$ 35,374,973
Balance (in shares) at Dec. 31, 2022	43,635,715
Stock-based compensation - employees, consultants and directors		1,400,516			1,400,516
Issuance of common stock offerings, net of fees	$ 428	1,474,296			1,474,724
Issuance of common stock offerings, net of fees (in shares)	428,270
Legal/audit fees related to ATM offering		(56,702)			(56,702)
Proceeds from exercise of stock options for cash	$ 75	197,304			197,379
Proceeds from exercise of stock options for cash (in shares)	74,393
Issuance of restricted stock units	$ 55	183,600			183,655
Issuance of restricted stock units (in shares)	55,318
Other comprehensive income (loss): foreign translation adjustment			(1,000,882)		(1,000,882)
Net loss				(13,478,967)	(13,478,967)
Balance at Jun. 30, 2023	$ 44,193	290,199,035	1,328,313	(267,476,845)	24,094,696
Balance (in shares) at Jun. 30, 2023	44,193,696
Balance at Dec. 31, 2022	$ 43,635	287,000,021	2,329,195	(253,997,878)	35,374,973
Balance (in shares) at Dec. 31, 2022	43,635,715
Balance at Dec. 31, 2023	$ 54,240	305,196,874	529,321	(282,505,272)	23,275,163
Balance (in shares) at Dec. 31, 2023	54,240,265
Balance at Mar. 31, 2023	$ 43,851	288,514,368	1,720,987	(261,323,761)	28,955,445
Balance (in shares) at Mar. 31, 2023	43,851,380
Stock-based compensation - employees, consultants and directors		570,235			570,235
Issuance of common stock offerings, net of fees	$ 231	776,060			776,291
Issuance of common stock offerings, net of fees (in shares)	230,605
Proceeds from exercise of stock options for cash	$ 56	154,772			154,828
Proceeds from exercise of stock options for cash (in shares)	56,393
Issuance of restricted stock units	$ 55	183,600			183,655
Issuance of restricted stock units (in shares)	55,318
Other comprehensive income (loss): foreign translation adjustment			(392,674)		(392,674)
Net loss				(6,153,084)	(6,153,084)
Balance at Jun. 30, 2023	$ 44,193	290,199,035	1,328,313	(267,476,845)	24,094,696
Balance (in shares) at Jun. 30, 2023	44,193,696
Balance at Dec. 31, 2023	$ 54,240	305,196,874	529,321	(282,505,272)	23,275,163
Balance (in shares) at Dec. 31, 2023	54,240,265
Stock-based compensation - employees, consultants and directors		1,562,788			1,562,788
Warrants issued in connection with long-term debt		690,709			690,709
Issuance of common stock offerings, net of fees	$ 54	53,186			53,240
Issuance of common stock offerings, net of fees (in shares)	53,290
Issuance of restricted stock units	$ 12	11,201			11,213
Issuance of restricted stock units (in shares)	12,860
Other comprehensive income (loss): foreign translation adjustment			1,644,497		1,644,497
Net loss				(10,501,007)	(10,501,007)
Balance at Jun. 30, 2024	$ 54,306	307,514,758	2,173,818	(293,006,279)	16,736,603
Balance (in shares) at Jun. 30, 2024	54,306,415
Balance at Mar. 31, 2024	$ 54,294	305,984,268	1,752,496	(288,863,133)	18,927,925
Balance (in shares) at Mar. 31, 2024	54,293,555
Stock-based compensation - employees, consultants and directors		828,580			828,580
Warrants issued in connection with long-term debt		690,709			690,709
Issuance of restricted stock units	$ 12	11,201			11,213
Issuance of restricted stock units (in shares)	12,860
Other comprehensive income (loss): foreign translation adjustment			421,322		421,322
Net loss				(4,143,146)	(4,143,146)
Balance at Jun. 30, 2024	$ 54,306	$ 307,514,758	$ 2,173,818	$ (293,006,279)	$ 16,736,603
Balance (in shares) at Jun. 30, 2024	54,306,415

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (10,501,007)	$ (13,478,967)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued final fee	111,422	21,429
Non-cash compensation	199,096	(105,488)
Depreciation and amortization	797,873	660,589
Amortization of right-of-use asset	91,854	110,881
Write off of patent cost	249,642	292,806
Bad debt expense (recovery)	29,120	13,384
Stock-based compensation	1,562,792	1,400,516
Foreign currency translation (gain) loss	1,969,916	(1,075,656)
Changes in operating assets and liabilities:
Grants and accounts receivable	(1,952,413)	(1,271,716)
Inventories	(725,998)	1,449,881
Prepaid expenses and other current assets	574,181	1,649,776
Other assets	1,124
Accounts payable and accrued expenses	(2,032,014)	291,068
Net cash used in operating activities	(9,624,412)	(10,041,497)
Cash flows from investing activities:
Purchases of property and equipment	(63,421)	(300,221)
Payments for patent costs	(183,462)	(242,378)
Net cash used in investing activities	(246,883)	(542,599)
Cash flows from financing activities:
Proceeds from long-term debt	15,000,000
Repayment of long-term debt	(5,000,000)
Payment of final fee	(150,000)
Payment of loan costs	(640,375)
Equity contributions - net of fees incurred	53,250	1,418,022
Proceeds from exercise of stock options		197,379
Net cash provided by (used in) financing activities	9,262,875	1,615,401
Effect of exchange rates on cash	(64,009)	(24,348)
Net change in cash, cash equivalents and restricted cash	(672,429)	(8,993,043)
Cash, cash equivalents and restricted cash - beginning of period	15,615,095	23,832,026
Cash, cash equivalents and restricted cash - end of period	14,942,666	14,838,983
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	537,672	173,334
Supplemental disclosure of non-cash financing activities:
Warrants issued in connection with long-term debt	690,709
Issuance of restricted stock units	$ 11,213	$ 183,655

BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2024

BASIS OF PRESENTATION

BASIS OF PRESENTATION

1. BASIS OF PRESENTATION

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2024

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

Stock Market Listing

Basis of Consolidation and Foreign Currency Translation

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:


	June 30, 2024		December 31, 2023
Cash and cash equivalents	$	8,458,708	$	14,131,137
Restricted cash		6,483,958		1,483,958
Total cash, cash equivalents and restricted cash	$	14,942,666	$	15,615,095

Restricted Cash

Grants and Accounts Receivable

The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible.

The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods:

Inventories

Property and Equipment

Patents

Impairment or Disposal of Long-Lived Assets

Revenue Recognition

Research and Development and Clinical Trial Expenses

All research and development costs, payments to laboratories and research consultants are expensed when incurred.

Advertising Expenses

Income Taxes

The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company.

Use of Estimates

Concentration of Credit Risk

Financial Instruments

Warrants

Net Loss Per Common Share

Stock-Based Compensation

Shipping and Handling Costs

Effect of Recent Accounting Pronouncements

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2024

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

3. STOCKHOLDERS’ EQUITY

Preferred Stock

Common Stock

Shelf Registration

Open Market Sale Agreement with Jefferies LLC

Stock-Based Compensation

The summary of the stock option activity for the six months ended June 30, 2024 is as follows:


				Weighted
		Weighted		Average
		Average		Remaining
		Exercise Price		Contractual
	Shares	per Share		Life (Years)
Outstanding, December 31, 2023	10,548,174	$	4.49	7.01
Granted	3,378,366	$	0.95	—
Forfeited	(906,166)	$	2.78	—
Expired	(545,536)	$	5.31	—
Exercised	—	$	—	—
Outstanding, June 30, 2024	12,474,838	$	3.62	7.40

The intrinsic value is calculated as the difference between the market value of the shares as of June 30, 2024 of $0.703 and the exercise price of the shares.


Options Outstanding
	Number	Weighted		Weighted
Range of	Outstanding at	Average		Average	Aggregate
Exercise	June 30,	Exercise		Remaining	Intrinsic
Price	2024	Price		Life (Years)	Value
$0.84 - $13.20	12,474,838	$	3.62	7.4	$	—


Options Exercisable
Number	Weighted
Exercisable at	Average		Aggregate
June 30,	Exercise		Intrinsic
2024	Price		Value
5,385,858	$	5.91	$	—

The summary of the status of the Company’s non-vested options for the six months ended June 30, 2024 is as follows:


		Weighted
		Average
		Grant Date
	Shares	Fair Value

Non-vested, December 31, 2023	5,205,736	$	1.89
Granted	3,378,366	$	0.67
Forfeited	(906,166)	$	1.88
Vested	(588,956)	$	2.73
Non-vested, June 30, 2024	7,088,980	$	0.99

As of June 30, 2024, the Company had approximately $4,419,000 of total unrecognized compensation cost related to stock options which will be amortized over approximately 36 months.

During the six months ended June 30, 2024, 64,000 options were awarded to newly hired employees and consultants in connection with their employment or consulting agreements.

Change in Control-Based Awards of Restricted Stock Units:

The following table is a summary of these restricted stock units:


	Restricted Stock Units
	Board of	Executive	Other
	Directors	Management	Employees	Total	Intrinsic Value
December 31, 2023	346,500	779,500	1,697,500	2,823,500	$	3,134,085
Granted	—	—	156,250	156,250
Forfeited	—	—	(283,750)	(283,750)
June 30, 2024	346,500	779,500	1,570,000	2,696,000	$	1,926,044

Other Awards of Restricted Stock Units:

The following table outlines the restricted stock unit activity for the six months ended June 30, 2024:


		Weighted
		Average
		Grant Date
	Shares	Fair Value
Non-vested, December 31, 2023	430,505	$	3.31
Granted	373,000	$	0.96
Vested	(20,000)	$	6.59
Forfeited	(40,000)	$	3.73
Non-vested, June 30, 2024	743,505	$	2.02

Warrants:

REVENUE

6 Months Ended

Jun. 30, 2024

REVENUE

REVENUE

4. REVENUE

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended June 30, 2024:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	20,398	$	18,000	$	—	$	38,398
Germany		2,778,594		—		—		2,778,594
All other countries		1,673,812		4,350,985		—		6,024,797
Total product revenue		4,472,804		4,368,985		—		8,841,789
Grant and other income:
United States		—		—		1,052,847		1,052,847

Total revenue	$	4,472,804	$	4,368,985	$	1,052,847	$	9,894,636

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended June 30, 2023:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	6,583	$	—	$	—	$	6,583
Germany		3,168,448		—		—		3,168,448
All other countries		1,493,725		3,403,656		—		4,897,381
Total product revenue		4,668,756		3,403,656		—		8,072,412
Grant and other income:
United States		—		—		1,348,409		1,348,409

Total revenue	$	4,668,756	$	3,403,656	$	1,348,409	$	9,420,821

The following table disaggregates the Company’s revenue by customer type and geographic area for the six months ended June 30, 2024:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	42,014	$	36,000	$	—	$	78,014
Germany		6,316,321		—		—		6,316,321
All other countries		3,424,353		8,012,621		—		11,436,974
Total product revenue		9,782,688		8,048,621		—		17,831,309
Grant and other income:
United States		—		—		1,849,619		1,849,619

Total revenue	$	9,782,688	$	8,048,621	$	1,849,619	$	19,680,928

The following table disaggregates the Company’s revenue by customer type and geographic area for the six months ended June 30, 2023:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	10,353	$	—	$	—	$	10,353
Germany		6,506,352		—		—		6,506,352
All other countries		2,996,324		6,469,422		—		9,465,746
Total product revenue		9,513,029		6,469,422		—		15,982,451
Grant and other income:
United States		—		—		2,887,866		2,887,866

Total revenue	$	9,513,029	$	6,469,422	$	2,887,866	$	18,870,317

CytoSorb Sales

Most distributor’s/strategic partner’s contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories.

Government Grants

Cost plus – this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.

Performance based – the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.

The following table provides information about receivables and contract liabilities from contracts with customers:


	June 30, 2024		December 31, 2023
Receivables, which are included in grants and accounts receivable	$	5,906,808	$	3,846,271
Contract liabilities, which are included in accrued expenses and other current liabilities	$	1,298,050	$	1,573,141

LONG-TERM DEBT, NET

6 Months Ended

Jun. 30, 2024

LONG-TERM DEBT, NET

LONG-TERM DEBT, NET

5. LONG-TERM DEBT, NET

Avenue Capital Group:

Long-term debt consists of the following as of June 30, 2024:


Principal amount	$	15,000,000
Accrued final fee		900,000
Less unamortized debt discount		(1,588,209)
Less unamortized debt acquisition costs		(638,596)
Subtotal		13,673,195
Less Current maturities		—
Long-term debt net of current maturities	$	13,673,195

Principal payments of long-term debt are due as follows during the periods ending June 30:


2025	$	—
2026		—
2027		13,750,000
2028		1,250,000
Total	$	15,000,000

Bridge Bank:

2018 Success Fee Letter:

2022 Success Fee Letter:

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2024

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

6. COMMITMENTS AND CONTINGENCIES

Employment Agreements

Litigation

The Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation.

Royalty Agreements

License Agreement

LEASES

6 Months Ended

Jun. 30, 2024

LEASES

LEASES

7. LEASES

Right-Of-Use Asset and Lease Liability


	June 30,		December 31,
	2024		2023
Right-of-use asset	$	11,789,539	$	12,058,896

Total lease liability	$	13,092,792	$	13,270,295
Less current portion		(412,067)		(373,636)
Lease liability, net of current portion	$	12,680,725	$	12,896,659

The maturities of the lease liabilities are as follows for the periods ending June 30:


2025	$	1,676,044
2026		1,715,575
2027		1,756,193
2028		1,797,927
2029		1,840,810
Thereafter		14,487,274
Total lease payments		23,273,823
Present value discount		(10,181,031)
Total	$	13,092,792

As of June 30, 2024 and December 31, 2023, the weighted average remaining lease term was years 11.9 and 12.7 years, respectively.

NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2024

NET LOSS PER SHARE

NET LOSS PER SHARE

8. NET LOSS PER SHARE

Pay vs Performance Disclosure - USD ($)	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (4,143,146)	$ (6,153,084)	$ (10,501,007)	$ (13,478,967)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2024

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

Stock Market Listing

Basis of Consolidation and Foreign Currency Translation

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:


	June 30, 2024		December 31, 2023
Cash and cash equivalents	$	8,458,708	$	14,131,137
Restricted cash		6,483,958		1,483,958
Total cash, cash equivalents and restricted cash	$	14,942,666	$	15,615,095

Restricted Cash

Restricted Cash

Grants and Accounts Receivable

The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible.

The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods:

Inventories

Property and Equipment

Patents

Impairment or Disposal of Long-Lived Assets

Revenue Recognition

Research and Development and Clinical Trial Expenses

All research and development costs, payments to laboratories and research consultants are expensed when incurred.

Advertising Expenses

Income Taxes

The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company.

Use of Estimates

Concentration of Credit Risk

Financial Instruments

Warrants

Net Loss Per Common Share

Stock-Based Compensation

Shipping and Handling Costs

Effect of Recent Accounting Pronouncements

Effect of Recent Accounting Pronouncements

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2024

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents


	June 30, 2024		December 31, 2023
Cash and cash equivalents	$	8,458,708	$	14,131,137
Restricted cash		6,483,958		1,483,958
Total cash, cash equivalents and restricted cash	$	14,942,666	$	15,615,095

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2024

STOCKHOLDERS' EQUITY

Schedule of stock options activity


				Weighted
		Weighted		Average
		Average		Remaining
		Exercise Price		Contractual
	Shares	per Share		Life (Years)
Outstanding, December 31, 2023	10,548,174	$	4.49	7.01
Granted	3,378,366	$	0.95	—
Forfeited	(906,166)	$	2.78	—
Expired	(545,536)	$	5.31	—
Exercised	—	$	—	—
Outstanding, June 30, 2024	12,474,838	$	3.62	7.40

Schedule of intrinsic value

The intrinsic value is calculated as the difference between the market value of the shares as of June 30, 2024 of $0.703 and the exercise price of the shares.


Options Outstanding
	Number	Weighted		Weighted
Range of	Outstanding at	Average		Average	Aggregate
Exercise	June 30,	Exercise		Remaining	Intrinsic
Price	2024	Price		Life (Years)	Value
$0.84 - $13.20	12,474,838	$	3.62	7.4	$	—


Options Exercisable
Number	Weighted
Exercisable at	Average		Aggregate
June 30,	Exercise		Intrinsic
2024	Price		Value
5,385,858	$	5.91	$	—

Schedule of company's non-vested options


		Weighted
		Average
		Grant Date
	Shares	Fair Value

Non-vested, December 31, 2023	5,205,736	$	1.89
Granted	3,378,366	$	0.67
Forfeited	(906,166)	$	1.88
Vested	(588,956)	$	2.73
Non-vested, June 30, 2024	7,088,980	$	0.99

Schedule of restricted stock unit


	Restricted Stock Units
	Board of	Executive	Other
	Directors	Management	Employees	Total	Intrinsic Value
December 31, 2023	346,500	779,500	1,697,500	2,823,500	$	3,134,085
Granted	—	—	156,250	156,250
Forfeited	—	—	(283,750)	(283,750)
June 30, 2024	346,500	779,500	1,570,000	2,696,000	$	1,926,044

Schedule of the restricted stock unit activity


		Weighted
		Average
		Grant Date
	Shares	Fair Value
Non-vested, December 31, 2023	430,505	$	3.31
Granted	373,000	$	0.96
Vested	(20,000)	$	6.59
Forfeited	(40,000)	$	3.73
Non-vested, June 30, 2024	743,505	$	2.02

REVENUE (Tables)

6 Months Ended

Jun. 30, 2024

REVENUE

Schedule of disaggregation of revenue

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended June 30, 2024:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	20,398	$	18,000	$	—	$	38,398
Germany		2,778,594		—		—		2,778,594
All other countries		1,673,812		4,350,985		—		6,024,797
Total product revenue		4,472,804		4,368,985		—		8,841,789
Grant and other income:
United States		—		—		1,052,847		1,052,847

Total revenue	$	4,472,804	$	4,368,985	$	1,052,847	$	9,894,636

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended June 30, 2023:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	6,583	$	—	$	—	$	6,583
Germany		3,168,448		—		—		3,168,448
All other countries		1,493,725		3,403,656		—		4,897,381
Total product revenue		4,668,756		3,403,656		—		8,072,412
Grant and other income:
United States		—		—		1,348,409		1,348,409

Total revenue	$	4,668,756	$	3,403,656	$	1,348,409	$	9,420,821

The following table disaggregates the Company’s revenue by customer type and geographic area for the six months ended June 30, 2024:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	42,014	$	36,000	$	—	$	78,014
Germany		6,316,321		—		—		6,316,321
All other countries		3,424,353		8,012,621		—		11,436,974
Total product revenue		9,782,688		8,048,621		—		17,831,309
Grant and other income:
United States		—		—		1,849,619		1,849,619

Total revenue	$	9,782,688	$	8,048,621	$	1,849,619	$	19,680,928

The following table disaggregates the Company’s revenue by customer type and geographic area for the six months ended June 30, 2023:


					United States
			Distributors/		Government
	Direct		Strategic Partners		Agencies		Total
Product sales:
United States	$	10,353	$	—	$	—	$	10,353
Germany		6,506,352		—		—		6,506,352
All other countries		2,996,324		6,469,422		—		9,465,746
Total product revenue		9,513,029		6,469,422		—		15,982,451
Grant and other income:
United States		—		—		2,887,866		2,887,866

Total revenue	$	9,513,029	$	6,469,422	$	2,887,866	$	18,870,317

Schedule of receivables and contract liabilities from contracts with customers


	June 30, 2024		December 31, 2023
Receivables, which are included in grants and accounts receivable	$	5,906,808	$	3,846,271
Contract liabilities, which are included in accrued expenses and other current liabilities	$	1,298,050	$	1,573,141

LONG-TERM DEBT, NET (Tables)

6 Months Ended

Jun. 30, 2024

LONG-TERM DEBT, NET

Schedule of Long-term debt

Long-term debt consists of the following as of June 30, 2024:


Principal amount	$	15,000,000
Accrued final fee		900,000
Less unamortized debt discount		(1,588,209)
Less unamortized debt acquisition costs		(638,596)
Subtotal		13,673,195
Less Current maturities		—
Long-term debt net of current maturities	$	13,673,195

Schedule of Principal payments of long-term debt

Principal payments of long-term debt are due as follows during the periods ending June 30:


2025	$	—
2026		—
2027		13,750,000
2028		1,250,000
Total	$	15,000,000

LEASES (Tables)

6 Months Ended

Jun. 30, 2024

LEASES

Schedule of right-of- use asset and related lease liability


	June 30,		December 31,
	2024		2023
Right-of-use asset	$	11,789,539	$	12,058,896

Total lease liability	$	13,092,792	$	13,270,295
Less current portion		(412,067)		(373,636)
Lease liability, net of current portion	$	12,680,725	$	12,896,659

Schedule of maturities of the lease liabilities

The maturities of the lease liabilities are as follows for the periods ending June 30:


2025	$	1,676,044
2026		1,715,575
2027		1,756,193
2028		1,797,927
2029		1,840,810
Thereafter		14,487,274
Total lease payments		23,273,823
Present value discount		(10,181,031)
Total	$	13,092,792

BASIS OF PRESENTATION (Details) - USD ($)	6 Months Ended
BASIS OF PRESENTATION (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
BASIS OF PRESENTATION
Cash and cash equivalents gross value	$ 14,900,000
Cash and cash equivalents	8,458,708	$ 14,131,137
Restricted cash	6,500,000
Maximum
BASIS OF PRESENTATION
Increase in unrestricted cash related to debt facility	$ 10,000,000

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2022 Institution state	Jun. 30, 2024 USD ($) patent Distributor $ / shares	Jun. 30, 2023 USD ($) Distributor	Jun. 30, 2024 USD ($) Distributor item patent country $ / shares	Jun. 30, 2023 USD ($) Distributor	Dec. 31, 2023 USD ($) Distributor $ / shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 17, 2014 $ / shares
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of countries where the entity's flagship product is marketed and distributed \| country				75
Preferred supplier agreement term	3 years
Number of healthcare facilities \| Institution	170
Number of states healthcare facilities across throughout Germany \| state	14
Number of patents \| patent		22		22
Common Stock, Par Value (in dollars per share) \| $ / shares		$ 0.001		$ 0.001		$ 0.001			$ 0.001
Foreign currency transaction gain (loss)		$ (544,000)	$ 415,000	$ (1,970,000)	$ 1,076,000
Restricted cash		6,483,958		6,483,958		$ 1,483,958
Inventory - finished goods		2,459,604		2,459,604		2,155,457
Inventory - work in process		1,048,360		1,048,360		838,871
Inventory - raw materials		808,788		808,788		685,801
Impairment charges		185,000	21,000	250,000	293,000
Advertising expenses		93,000	38,000	138,000	93,000
Unrecognized tax benefits		0		$ 0		$ 2,100,000
Number of member bank \| item				4,000
Cost of revenue		3,391,907	3,402,271	$ 6,607,621	7,396,440
Debt agreement
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Restricted cash		5,000,000		5,000,000
Federal
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Federal statutory rate							21.00%	35.00%
Letter of credit
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash collateral		1,467,458		1,467,458
Credit Card
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash collateral		16,500		16,500
Cargo and Freight
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cost of revenue		$ 64,000	$ 122,000	$ 178,000	$ 200,000
Accounts receivable \| Customer concentration risk \| Distributors/Strategic Partners
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of distributors \| Distributor				2		1
Concentration risk percentage				30.00%		19.00%
Revenue \| Customer concentration risk \| Distributors/Strategic Partners
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of distributors \| Distributor		1	1	1	1
Concentration risk percentage		14.00%	12.00%	12.00%	11.00%

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and cash equivalents	$ 8,458,708	$ 14,131,137
Restricted cash	6,483,958	1,483,958
Total cash, cash equivalents and restricted cash	$ 14,942,666	$ 15,615,095	$ 14,838,983	$ 23,832,026

STOCKHOLDERS' EQUITY - Stock option activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Shares
Outstanding, beginning of the year	10,548,174
Granted	3,378,366
Forfeited	(906,166)
Expired	(545,536)
Outstanding, end of the year	12,474,838	10,548,174
Weighted Average Exercise Price per Share
Outstanding, beginning of the year	$ 4.49
Granted	0.95
Forfeited	2.78
Expired	5.31
Outstanding, end of the year	$ 3.62	$ 4.49
Weighted Average Remaining Contractual Life (Years)
Outstanding, beginning of the year		7 years 3 days
Granted	0 years
Forfeited	0 years
Expired	0 years
Exercised	0 years
Outstanding, end of the year	7 years 4 months 24 days

STOCKHOLDERS' EQUITY - Intrinsic value (Details)	6 Months Ended
STOCKHOLDERS' EQUITY - Intrinsic value (Details)	Jun. 30, 2024 $ / shares shares
Options Exercisable
Number Exercisable at June 30, 2024 \| shares	5,385,858
Weighted Average Exercise Price	$ 5.91
Exercise Price Range One
Options Outstanding
Range of Exercise Price, Lower Range Limit	0.84
Range of Exercise Price, Upper Range Limit	$ 13.20
Number Outstanding at June 30, 2024 \| shares	12,474,838
Weighted Average Exercise Price	$ 3.62
Weighted Average Remaining Life (Years)	7 years 4 months 24 days

STOCKHOLDERS' EQUITY - Non-vested options (Details)	6 Months Ended
STOCKHOLDERS' EQUITY - Non-vested options (Details)	Jun. 30, 2024 $ / shares shares
Shares
Non-vested, December 31, 2023 \| shares	5,205,736
Granted \| shares	3,378,366
Forfeited \| shares	(906,166)
Vested \| shares	(588,956)
Non-vested, June 30, 2024 \| shares	7,088,980
Weighted Average Grant Date Fair Value
Non-vested, December 31, 2023 \| $ / shares	$ 1.89
Granted \| $ / shares	0.67
Forfeited \| $ / shares	1.88
Vested \| $ / shares	2.73
Non-vested, June 30, 2024 \| $ / shares	$ 0.99

STOCKHOLDERS' EQUITY - Restricted stock unit (Details) - Restricted stock - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
STOCKHOLDERS' EQUITY
Restricted Stock Units, Beginning Balance			2,823,500
Restricted Stock Units, Intrinsic Value Beginning Balance			$ 3,134,085
Granted			156,250
Forfeited			(283,750)
Restricted Stock Units, Ending Balance	2,696,000		2,696,000
Restricted Stock Units, Intrinsic Value Ending Balance	$ 1,926,044		$ 1,926,044
Restricted Stock Units, Expense	$ 0	$ 0	$ 0	$ 0
Board of Directors
STOCKHOLDERS' EQUITY
Restricted Stock Units, Beginning Balance			346,500
Granted			0
Forfeited			0
Restricted Stock Units, Ending Balance	346,500		346,500
Executive Management
STOCKHOLDERS' EQUITY
Restricted Stock Units, Beginning Balance			779,500
Granted			0
Forfeited			0
Restricted Stock Units, Ending Balance	779,500		779,500
Other Employees
STOCKHOLDERS' EQUITY
Restricted Stock Units, Beginning Balance			1,697,500
Granted			156,250
Forfeited			(283,750)
Restricted Stock Units, Ending Balance	1,570,000		1,570,000

STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details) - Restricted stock	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Shares
Non-vested, December 31, 2023 \| shares	430,505
Granted \| shares	373,000
Vested \| shares	(20,000)
Forfeited \| shares	(40,000)
Non-vested, June 30, 2024 \| shares	743,505
Weighted Average Grant Date Fair Value
Non-vested, December 31, 2023 \| $ / shares	$ 3.31
Granted \| $ / shares	0.96
Vested \| $ / shares	6.59
Forfeited \| $ / shares	3.73
Non-vested, June 30, 2024 \| $ / shares	$ 2.02

STOCKHOLDERS' EQUITY - Warrants (Details) - $ / shares		6 Months Ended
STOCKHOLDERS' EQUITY - Warrants (Details) - $ / shares	Jun. 28, 2024	Jun. 30, 2024	Dec. 31, 2023
STOCKHOLDERS' EQUITY
Number of shares to be purchased		4,352,130	2,706,561
Warrant exercise price per share			$ 2.00
Stock price trigger for revision of exercise price of warrants	$ 0.79
Loan and security agreement
STOCKHOLDERS' EQUITY
Warrant exercise price per share	$ 0.79	$ 0.79
Class of warrant issued	1,645,569
Stock price trigger for revision of exercise price of warrants		$ 0.79

STOCKHOLDERS' EQUITY - Additional information (Details)								3 Months Ended		6 Months Ended			12 Months Ended
STOCKHOLDERS' EQUITY - Additional information (Details)	Apr. 08, 2024 USD ($) shares	Apr. 02, 2024 USD ($) shares	Mar. 29, 2024 USD ($) shares	Sep. 18, 2023 USD ($) shares	Jul. 07, 2023 USD ($) shares	Aug. 10, 2022 USD ($) shares	Dec. 30, 2021 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USN ($) shares	Jun. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 shares	Jul. 26, 2024 USD ($)	Jul. 14, 2021 USD ($)	Jun. 30, 2019 shares
STOCKHOLDERS' EQUITY
Number of preferred stock authorized								5,000,000		5,000,000			5,000,000				5,000,000
Common Stock, shares authorized								100,000,000		100,000,000			100,000,000
Issuance of common stock														0
Aggregate registered amount for offerings \| $																$ 150,000,000
Restricted stock unit \| $								$ 829,000	$ 570,000	$ 1,563,000		$ 1,401,000
Grant date exercise price range \| $ / shares								$ 0.703		$ 0.703
Total unrecognized compensation cost related to stock options \| $								$ 4,419,000		$ 4,419,000
Amortized period										36 months	36 months
Vested										588,956	588,956
Outstanding								12,474,838		12,474,838			10,548,174
Issuance of restricted stock units \| $								$ 11,213	$ 183,655	$ 11,213		$ 183,655
Maximum
STOCKHOLDERS' EQUITY
Common Stock, shares authorized																	100,000,000
Minimum
STOCKHOLDERS' EQUITY
Common Stock, shares authorized																	50,000,000
Common Stock
STOCKHOLDERS' EQUITY
Issuance of common stock									230,605	53,290	53,290	428,270
Issuance of restricted stock units \| $								$ 12	$ 55	$ 12		$ 55
Restricted stock
STOCKHOLDERS' EQUITY
Options to grant (in shares)										373,000	373,000
RSU Forfeited (in shares)										40,000	40,000
Vested (in shares)										20,000	20,000
Non-Vested shares								743,505		743,505			430,505
Director \| Common Stock
STOCKHOLDERS' EQUITY
Unvested options in fair value \| $		$ 71,000
Number of options granted		110,000
Employee one \| Common Stock
STOCKHOLDERS' EQUITY
Unvested options in fair value \| $	$ 85,000	$ 830,000
Number of options granted	131,339	1,214,400
Employee one \| Common Stock \| Vesting, tranche one
STOCKHOLDERS' EQUITY
Vesting percentage		0.50%
Employee one \| Common Stock \| Vesting, tranche two
STOCKHOLDERS' EQUITY
Vesting percentage		0.25%
Employee one \| Common Stock \| Vesting, tranche three
STOCKHOLDERS' EQUITY
Vesting percentage		0.25%
Employee Stock
STOCKHOLDERS' EQUITY
Outstanding								64,000		64,000
Employee two \| Common Stock
STOCKHOLDERS' EQUITY
Unvested options in fair value \| $		$ 594,000
Number of options granted		922,147
Chief Executive Officer \| Vesting, tranche one
STOCKHOLDERS' EQUITY
Unvested options in fair value \| $			$ 249,000
Chief Executive Officer \| Common Stock
STOCKHOLDERS' EQUITY
Number of options granted			380,480
Senior managers \| Common Stock
STOCKHOLDERS' EQUITY
Unvested options in fair value \| $		$ 380,000
Number of options granted		556,000
Senior managers \| Common Stock \| Vesting, tranche one
STOCKHOLDERS' EQUITY
Vesting percentage		0.50%
Senior managers \| Common Stock \| Vesting, tranche two
STOCKHOLDERS' EQUITY
Vesting percentage		0.25%
Senior managers \| Common Stock \| Vesting, tranche three
STOCKHOLDERS' EQUITY
Vesting percentage		0.25%
Senior managers \| Restricted stock
STOCKHOLDERS' EQUITY
Restricted stock unit \| $								$ 40,000		$ 40,000
Stock issued during period, value, restricted stock sward, gross \| $		$ 328,000
Options to grant (in shares)		343,000
Executive officers and senior managers \| Restricted stock
STOCKHOLDERS' EQUITY
Restricted stock unit								47,000	47,000		$ 94,000	94,000
Stock issued during period, shares, restricted stock award, gross						288,500
Stock issued during period, value, restricted stock sward, gross \| $						$ 563,000
Executive officers and senior managers \| Restricted stock
STOCKHOLDERS' EQUITY
Restricted stock unit \| $								110,000		221,000
Stock issued during period, shares, restricted stock award, gross					250,000
Stock issued during period, value, restricted stock sward, gross \| $					$ 883,000
Executive officer \| Restricted stock
STOCKHOLDERS' EQUITY
Restricted stock unit \| $								5,000		10,000
Vested				25,000
Stock issued during period, shares, restricted stock award, gross				45,000
Stock issued during period, value, restricted stock sward, gross \| $				$ 89,000
Executive officer \| Restricted stock \| Vesting, tranche one
STOCKHOLDERS' EQUITY
Vested				10,000
Executive officer \| Restricted stock \| Vesting, tranche two
STOCKHOLDERS' EQUITY
Vested				10,000
Certain employees \| Vesting, tranche one \| Anniversary of the award
STOCKHOLDERS' EQUITY
Vesting percentage		0.33%
Certain employees \| Vesting, tranche two \| Anniversary of the award
STOCKHOLDERS' EQUITY
Vesting percentage		0.33%
Certain employees \| Vesting, tranche three \| Anniversary of the award
STOCKHOLDERS' EQUITY
Vesting percentage		0.33%
Certain employees \| Restricted stock
STOCKHOLDERS' EQUITY
Restricted stock unit \| $								$ (191,000)	$ 19,000	$ (163,000)		$ 46,000
Options to grant (in shares)		103,000
Issuance of restricted stock units \| $		$ 410,000
RSU Forfeited (in shares)								40,000
RSU Forfeited \| $								$ 149,000
Vested (in shares)								20,000
Vested \| $								$ 132,000
Certain employees \| Restricted stock \| Anniversary of the award
STOCKHOLDERS' EQUITY
Non-Vested shares		13,000
Certain employees \| Restricted stock \| Vesting upon earlier of change in control or three years from date of award
STOCKHOLDERS' EQUITY
Vesting period		3 years
Non-Vested shares		30,000
Jefferies LLC and B. Riley FBR, Inc
STOCKHOLDERS' EQUITY
Issuance of common stock										53,290	53,290		2,656,464
Aggregate offering price \| $							$ 25,000,000
Net proceeds from issuance of stock \| $										$ 53,000			$ 4,532,000
Commission rate (as a percent)								3.00%		3.00%
Net proceeds from issuance of stock \| $													$ 61,000
Average selling price \| $ / shares								$ 1.03		$ 1.03			$ 1.76
Exercise Price Ranging From 0.84 to 0.99
STOCKHOLDERS' EQUITY
Expected life of the stock option										6 years	6 years
Current price of the underlying stock and its expected volatility range										76.60%	76.60%
Expected dividends										0.00%	0.00%
Risk free interest rate, minimum										3.86%	3.86%
Risk free interest rate range										4.65%	4.65%
Exercise Price Ranging From 0.84 to 0.99 \| Maximum
STOCKHOLDERS' EQUITY
Grant date exercise price range \| $ / shares								0.99		$ 0.99
Exercise Price Ranging From 0.84 to 0.99 \| Minimum
STOCKHOLDERS' EQUITY
Grant date exercise price range \| $ / shares								$ 0.84		$ 0.84
Subsequent event
STOCKHOLDERS' EQUITY
Aggregate registered amount for offerings \| $															$ 150,000,000

REVENUE - Revenue by customer type and geographic area (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Product sales:
Total revenue	$ 9,894,636	$ 9,420,821	$ 19,680,928	$ 18,870,317
Total product sales
Product sales:
Total revenue	8,841,789	8,072,412	17,831,309	15,982,451
Grant income
Product sales:
Total revenue	1,052,847	1,348,409	1,849,619	2,887,866
United States \| Total product sales
Product sales:
Total revenue	38,398	6,583	78,014	10,353
United States \| Grant income
Product sales:
Total revenue	1,052,847	1,348,409	1,849,619	2,887,866
Germany \| Total product sales
Product sales:
Total revenue	2,778,594	3,168,448	6,316,321	6,506,352
All other countries \| Total product sales
Product sales:
Total revenue	6,024,797	4,897,381	11,436,974	9,465,746
Direct
Product sales:
Total revenue	4,472,804	4,668,756	9,782,688	9,513,029
Direct \| Total product sales
Product sales:
Total revenue	4,472,804	4,668,756	9,782,688	9,513,029
Direct \| United States \| Total product sales
Product sales:
Total revenue	20,398	6,583	42,014	10,353
Direct \| Germany \| Total product sales
Product sales:
Total revenue	2,778,594	3,168,448	6,316,321	6,506,352
Direct \| All other countries \| Total product sales
Product sales:
Total revenue	1,673,812	1,493,725	3,424,353	2,996,324
Distributors/Strategic Partners
Product sales:
Total revenue	4,368,985	3,403,656	8,048,621	6,469,422
Distributors/Strategic Partners \| Total product sales
Product sales:
Total revenue	4,368,985	3,403,656	8,048,621	6,469,422
Distributors/Strategic Partners \| United States \| Total product sales
Product sales:
Total revenue	18,000		36,000
Distributors/Strategic Partners \| All other countries \| Total product sales
Product sales:
Total revenue	4,350,985	3,403,656	8,012,621	6,469,422
United States Government Agencies
Product sales:
Total revenue	1,052,847	1,348,409	1,849,619	2,887,866
United States Government Agencies \| United States \| Grant income
Product sales:
Total revenue	$ 1,052,847	$ 1,348,409	$ 1,849,619	$ 2,887,866

REVENUE - Receivables and contract liabilities (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
REVENUE
Receivables, which are included in grants and accounts receivable	$ 5,906,808	$ 3,846,271
Contract liabilities, which are included in accrued expenses and other current liabilities	$ 1,298,050	$ 1,573,141

REVENUE - Additional information (Details)	6 Months Ended
REVENUE - Additional information (Details)	Jun. 30, 2024 USD ($) segment	Dec. 31, 2023 USD ($)
REVENUE
Number of primary revenue streams \| segment	2
Term of customer contracts	3 years
Value of free of charge goods and credit rebates	$ 201,887	$ 196,322
Contract liabilities net of value of free of charge goods and credit rebates	1,096,163	1,376,819
Receivables, which are included in grants and accounts receivable	5,906,808	3,846,271
Product sales
REVENUE
Receivables, which are included in grants and accounts receivable	5,424,751	3,270,724
Government grants
REVENUE
Receivables, which are included in grants and accounts receivable	$ 482,057	$ 575,547
Maximum
REVENUE
Term of customer contracts	5 years
Minimum
REVENUE
Term of customer contracts	1 year

LONG-TERM DEBT, NET - Avenue Capital Group (Details) - USD ($)		3 Months Ended	6 Months Ended
	Jun. 28, 2024	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
LONG-TERM DEBT
Restricted cash		$ 6,483,958	$ 6,483,958	$ 1,483,958
Warrant Exercise Price per Share				$ 2.00
Stock price trigger for revision of exercise price of warrants	$ 0.79
Warrants issued in connection with long-term debt		690,709	690,709
Debt agreement
LONG-TERM DEBT
Maximum borrowing capacity		20,000,000	20,000,000
Debt instrument unused capacity		10,000,000	10,000,000
Restricted cash		5,000,000	5,000,000
Minimum net proceeds from sale of equity securities, considered for release of restricted cash		3,000,000	$ 3,000,000
Interest rate			5.00%
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]			us-gaap:PrimeRateMember
Period for monthly interest only payments			25 months
Extension term of loan			30 months
Percentage of commitment fee			1.00%
Payment of financial advisor and legal fees			$ 640,000
Interest expense			$ 2,000
Percentage of final payment			4.50%
Interest expense		$ 2,500	$ 2,500
Minimum period after entry, over which any judgment(s) singly or in the aggregate in excess of the Threshold Amount remain unsatisfied, unvacated or unstayed, considered for events of default to trigger accelerated repayment			15 days
Period within which any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of default to trigger accelerated repayment			45 days
Warrants to purchase shares		1,645,569	1,645,569
Warrant Exercise Price per Share	$ 0.79	$ 0.79	$ 0.79
Stock price trigger for revision of exercise price of warrants			$ 0.79
Conversion of debt into common stock		$ 2,000,000	$ 2,000,000
Fixed conversion price of closing stock			120.00%
Fixed conversion price of closing stock, Per share			0.95%
Debt agreement \| Prepayment made on or after funding date
LONG-TERM DEBT
Prepayment percentage			3.00%
Debt agreement \| Prepayment made after first anniversary
LONG-TERM DEBT
Prepayment percentage			2.00%
Debt agreement \| Prepayment made after second anniversary
LONG-TERM DEBT
Prepayment percentage			1.00%
Debt agreement \| Maximum
LONG-TERM DEBT
Release of restricted cash upon equity raise		5,000,000	$ 5,000,000
Debt agreement \| Minimum
LONG-TERM DEBT
Release of restricted cash upon equity raise		$ 3,000,000	$ 3,000,000
Effective rate		13.50%	13.50%
Growth Capital Loan Tranche 1
LONG-TERM DEBT
Debt instrument face amount		$ 15,000,000	$ 15,000,000
Growth Capital Loan Tranche 1 \| Avenue Venture Opportunities Fund, L.P
LONG-TERM DEBT
Debt instrument face amount		4,500,000	4,500,000
Growth Capital Loan Tranche 1 \| Avenue Venture Opportunities Fund II, L.P
LONG-TERM DEBT
Debt instrument face amount		10,500,000	10,500,000
Growth Capital Loan Tranche 2
LONG-TERM DEBT
Maximum borrowing capacity		$ 5,000,000	$ 5,000,000

LONG-TERM DEBT, NET (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
LONG-TERM DEBT, NET
Principal amount	$ 15,000,000
Accrued final fee	900,000
Less unamortized debt discount	(1,588,209)
Less unamortized debt acquisition costs	(638,596)
Subtotal	13,673,195
Less Current maturities		$ (2,500,000)
Long-term debt net of current maturities	$ 13,673,195	$ 2,542,857

LONG-TERM DEBT, NET - Principal payments (Details)	Jun. 30, 2024 USD ($)
LONG-TERM DEBT, NET
2027	$ 13,750,000
2028	1,250,000
Total	$ 15,000,000

LONG-TERM DEBT, NET - Additional information (Details)	6 Months Ended
LONG-TERM DEBT, NET - Additional information (Details)	Jun. 30, 2024 USD ($) $ / shares
2022 Success Fee Letter \| First Tranche
LONG-TERM DEBT
Maximum borrowing capacity \| $	$ 5,000,000
Percentage of success fee	1.00%
Average selling price	$ 8
Number of days for stock price threshold set in success fee letter	5 days
2022 Success Fee Letter \| Second Tranche
LONG-TERM DEBT
Maximum borrowing capacity \| $	$ 5,000,000
Percentage of success fee	1.50%
Average selling price	$ 10
Number of days for stock price threshold set in success fee letter	5 days
2022 Success Fee Letter \| Third Tranche
LONG-TERM DEBT
Maximum borrowing capacity \| $	$ 5,000,000
Percentage of success fee	2.00%
Average selling price	$ 12
Number of days for stock price threshold set in success fee letter	5 days
Western Alliance Bank \| 2018 Success Fee Letter
LONG-TERM DEBT
Percentage of success fee	6.37%
Average selling price	$ 7.05
Number of days for stock price threshold set in success fee letter	5 days
Western Alliance Bank \| 2018 Success Fee Letter \| Minimum
LONG-TERM DEBT
Percentage of closing price on common stock	26.13%
Western Alliance Bank \| 2018 Success Fee Letter \| Maximum
LONG-TERM DEBT
Percentage of closing price on common stock	70.00%

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Apr. 12, 2020	Aug. 11, 2003	Jan. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
COMMITMENTS AND CONTINGENCIES
Initial term (in years)						3 years
Automatic renewal period for employment agreements	1 year
Additional automatic renewed period for employment agreements			1 year
Royalty Agreement
COMMITMENTS AND CONTINGENCIES
Equity investment by an existing investor		$ 4,000,000
Future royalty payment percentage on gross revenue		3.00%
Royalty cost				$ 264,000	$ 240,000	$ 531,000	$ 474,000
Percentage of royalty						0.90%
License Agreement
COMMITMENTS AND CONTINGENCIES
Royalty cost				$ 352,000	$ 320,000	$ 709,000	$ 632,000
Term of license agreement						18 years
Royalty rate, lower limit				2.50%		2.50%
Royalty rate, upper limit				5.00%		5.00%

LEASES (Details)		1 Months Ended			3 Months Ended		6 Months Ended
LEASES (Details)	Apr. 01, 2021 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($) item	Jan. 31, 2021 USD ($) m²	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Apr. 30, 2021 USD ($)	Apr. 01, 2020 USD ($)
LEASES:
Operating lease lability					$ 13,092,792		$ 13,092,792		$ 13,270,295
Right of use asset					$ 11,789,539		$ 11,789,539		$ 12,058,896
Incremental borrowing rate					9.80%		9.80%
Operating lease paid					$ 566,000	$ 466,000	$ 1,137,000	$ 1,099,000
Weighted average remaining lease term					11 years 10 months 24 days		11 years 10 months 24 days		12 years 8 months 12 days
CytoSorbents Medical, Inc
LEASES:
Number of times lease renewal options available \| item			2
Renewal term			5 years
Rent abatement term			6 months
CytoSorbents Europe GmbH
LEASES:
Monthly payments of base rent and other costs				$ 7,784
Operating lease lability											$ 594,000
Right of use asset											$ 594,000
Area of Land \| m²				1,068
Other costs	$ 239
Lease term	5 years
Existence of option to extend	true
Additional lessee operating lease term of contract option to extend	5 years
United States \| CytoSorbents Medical, Inc
LEASES:
Remaining lease term			15 years 6 months
Annual rent expense increment rate			2.75%
Percentage of total building space occupied			92.30%
Allowance for building improvement			$ 1,455,000
Operating lease lability	$ 11,600,000
Right of use asset	$ 11,600,000
Incremental borrowing rate	9.80%
United States \| Letter of credit \| CytoSorbents Medical, Inc
LEASES:
Security amount										$ 1,467,000
United States \| Initial early term \| CytoSorbents Medical, Inc
LEASES:
Monthly payments of base rent and other costs			25,208
United States \| Early term \| CytoSorbents Medical, Inc
LEASES:
Monthly payments of base rent and other costs			88,254
United States \| Early term \| CytoSorbents Medical, Inc
LEASES:
Monthly payments of base rent and other costs			$ 111,171
Germany
LEASES:
Monthly payments of base rent and other costs		$ 12,100
Additional operating leases rent expense		$ 3,000

LEASES - Right-of- use asset and related lease liability (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
LEASES
Right-of-use asset	$ 11,789,539	$ 12,058,896
Total lease liability	13,092,792	13,270,295
Less current portion	(412,067)	(373,636)
Lease liability, net of current portion	$ 12,680,725	$ 12,896,659

LEASES - Maturities of the lease liabilities (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
LEASES
2025	$ 1,676,044
2026	1,715,575
2027	1,756,193
2028	1,797,927
2029	1,840,810
Thereafter	14,487,274
Total lease payments	23,273,823
Present value discount	(10,181,031)
Total lease liability	$ 13,092,792	$ 13,270,295

NET LOSS PER SHARE (Details) - shares	6 Months Ended
NET LOSS PER SHARE (Details) - shares	Jun. 30, 2024	Jun. 30, 2023
Stock options and warrants
NET LOSS PER SHARE
Antidilutive securities excluded from computation of earnings per share	20,266,000	11,904,000

CytoSorbents (NASDAQ:CTSO)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

Plus de graphiques de la Bourse CytoSorbents

CytoSorbents (NASDAQ:CTSO)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

CTSO CytoSorbents Corporation

Actualités CytoSorbents Corporation

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

CTSO CytoSorbents Corporation

Actualités CytoSorbents Corporation

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres